



(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 158(3) EPC

(43) Date of publication:
19.03.2003 Bulletin 2003/12

(21) Application number: **01930192.8**

(22) Date of filing: **17.05.2001**

(51) Int Cl.⁷: **C07D 249/08**, C07D 249/12,
C07D 401/04, C07D 413/14,
C07D 405/14, C07D 405/12,
C07D 405/04, A61K 31/41

(86) International application number:
PCT/JP01/04128

(87) International publication number:
WO 01/087855 (22.11.2001 Gazette 2001/47)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **19.05.2000 JP 2000148419**
23.02.2001 JP 2001047921

(71) Applicants:
• **YAMANOUCHI PHARMACEUTICAL CO. LTD.**
Tokyo 103-8411 (JP)
• **Merck Patent GmbH**
64293 Darmstadt (DE)

(72) Inventors:
• **TOBE, Takahiko**
Tsukuba-shi, Ibaraki 305-8585 (JP)
• **SUGANE, Takashi**
Tsukuba-shi, Ibaraki 305-8585 (JP)
• **HAMAGUCHI, Wataru**
Tsukuba-shi, Ibaraki 305-8585 (JP)

- **SHIMADA, Itsuro**
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **MAENO, Kyoichi**
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **MIYATA, Junji**
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **KIMIZUKA, Tetsuya**
Itabashi-ku, Tokyo 174-8612 (JP)
- **SUZUKI, Takeshi**
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **KOHARA, Atsuyuki**
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **MORITA, Takuma**
Tsukuba-shi, Ibaraki 305-8585 (JP)
- **ARLT, Michael**
64342 Seeheim Jugenheim (DE)
- **GREINER, Hartmut**
64331 Weiterstadt (DE)

(74) Representative: **Bates, Philip Ian**
Reddie & Grose
16 Theobalds Road
London WC1X 8PL (GB)

(54) **TRIAZOLE DERIVATIVES**

(57) The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various dis-

eases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.

Description

Technical Filed

5 **[0001]** The present invention relates to the pharmaceutical composition comprising triazole derivative as an effective ingredient, which is useful as an inhibitor of the activity of glycine transporter, and a novel triazole derivative with an action as an inhibitor of the activity of glycine transporter.

Background Art

10

[0002] Glycine is known as an excitatory and inhibitory neurotransmitter in the central and peripheral nervous systems. These functions work via two different types of receptors, in which different types of glycine transporter are independently involved. The function as an inhibitory neurotransmitter works via the strychnine-sensitive glycine receptor present mainly in spinal cord and brain stem. Alternatively, the function as an excitatory neurotransmitter works via N-methyl-D-aspartic acid (NMDA) receptor known as a subtype of glutamate receptors. Glycine is known as a coagonist for the NMDA receptor (Johnson J. W. and Asher P., Glycine potentiates the NMDA response in cultured mouse brain neurons, *Nature*, 325, 529-531, (1987)). The NMDA receptor is widely distributed in brain, particularly in cerebral cortex and hippocampus.

[0003] Neurotransmitter transporter plays a significant role in the control of the concentration of neurotransmitter in the synaptic cleft, by incorporating the neurotransmitter inside the cells. Additionally, it is considered that neurotransmitter transporter makes a contribution to the recycling of neurotransmitter, by incorporating the neurotransmitter into the presynapse terminus. It is considered that the control of the functions of neurotransmitter transporter is useful for therapeutically treating various diseased conditions due to abnormalities in nerve functions, through the control of the concentration of neurotransmitter in the synaptic cleft.

25 **[0004]** Glycine transporter (GLYT) was first cloned in 1992 (Guastella J., et al., Cloning, expression and localization
of a rat brain high-affinity glycine transporter, *Proc. Natl. Acad. Sci.*, 89, 7189-93, 1992). Two types of the transporters,
namely GLYT1 and GLYT2, have been identified so far (Liu Q.R., et al., Cloning and expression of a spinal cord- and
brain-specific glycine transporter with novel structural features, *J. Biol. Chem.*, 268, 22802-8, 1993). Furthermore, a
report tells that GLYT1 has several splicing variants (Kim K.M., et al., Cloning of the human glycine transporter type
30 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene
in the human and mouse genomes, *Mol. Pharmacol.*, 45, 608-17, 1994).

[0005] GLYT1 is expressed at a high density in spinal cord, brain stem, cerebellum, diencephalon and retina, while GLYT1 is expressed at a low density in olfactory bulb and cerebral hemisphere. It is considered that GLYT1 controls the NMDA receptor function (Smith K.E., et al., Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors, *Neuron*, 8, 927-35, 1992; Guastella J., et al., Cloning, expression, and localization of a rat brain high-affinity glycine transporter, *Proc. Natl. Acad. Sci.*, 89, 7189-93, 1992; and Bergeron, R., et al., Modulation of N-methyl-D-aspartate receptor function by glycine transport, *Proc. Natl. Acad. Sci. USA*, 95, 15730-15734, 1998). Javitt, et al. have reported that glycylododecylamide (GDA) as a glycine transporter inhibitor suppresses the enhancement of activity in mouse as induced by phencyclidine (PCP) as an NMDA receptor antagonist (Javitt D.C., et al., Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycylododecylaminide, *Neuropsychopharmacology*, 17, 202-4, 1997).

[0006] Alternatively, the expression of GLYT2 is limited to spinal cord, brain stem and cerebellum (Goebel D.J., Quantitative gene expression of two types of glycine transporter in the rat central nervous system, *Mol. Brain Res.*, 40, 139-42, 1996; Zafra F., et al., Glycine transporters are differentially expressed among CNS cells, *J. Neurosci.*, 15, 3952-69, 1995). Thus, it is considered that GLYT2 is involved in the control of the function of strychnine-sensitive glycine receptor. It is suggested that the inhibition of GLYT2 induces the attenuation of pain transmission in spinal cord via the enhancing action of strychnine-sensitive glycine receptor function (Yaksh, T.L., Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: effects of modulatory receptor systems and excitatory amino acid antagonists. *Pain*. 37, 111-123, 1989).

50 **[0007]** Furthermore, the enhancement of the strychnine-sensitive glycine receptor function is useful for the therapeutic treatment of abnormal muscular constriction such as spasm, myoclonus and epilepsy (Truong D.D., et al., Glycine involvement in DDT-induced myoclonus. *Movement Disorders*. 3,77-87, 1988; and Becker, C.M., et al., Disorders of the inhibitory glycine receptor: the spastic mouse, *FASEB J.* 4, 2767-2774, 1990). Spasm has a relation with nerve disorders and damages such as epilepsy, cerebrovascular disorders, head injuries, multiple sclerosis, spinal
55 injuries and dystonia.

[0008] It has been known that NMDA receptor has relations with various diseased conditions. It is suggested that the functional deterioration of NMDA receptor has a relation with schizophrenia (Javitt D.C. and Zukin S.R., Recent advances in the phencyclidine model of schizophrenia, *American Journal of Psychiatry*, 148, 1301-8, 1991). It is re-

ported that the negative symptoms of schizophrenic patients are ameliorated with a high dose of glycine (Heresco-Levy U., et al., Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia, *Br J Psychiatry*, 169, 610-7, 1996).

[0009] Additionally, the activation of NMDA receptor is involved in the formation of long-term potentiation (LTP) considered as a memory and learning model at the neuron level (Collingridge G.L. and Bliss T.V., NMDA receptors-their role in long-term potentiation. *Trends. Neurosci.*, 10, 288-93, 1987). Still additionally, the administration of an NMDA receptor antagonist to animals induces an amnesia therein (Morris R.G., Andersen E., Lynch G.S. and Braudy M., Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5, *Nature*, 319, 774-6, 1986; and Mark J. Benvenga and Theodore C. Spaulding, Amnesic effect of the novel anticonvulsant MK-801, *Pharmacol Biochem Behav.*, 30, 205-207, 1988). Hence, it is suggested that NMDA receptor plays a very significant role in memory and learning.

[0010] Further, the deterioration of the function of NMDA receptor has been reported even in humans, namely in patients with Alzheimer-type dementia (Ninomiya, H., et al., [³H]-N-[1-(2-thienyl)cyclo-hexyl]-3,4-piperidine ([³H]-TCP) binding in human frontal cortex: decreases in Alzheimer-type dementia., *J. Neurochem.*, 54, 526-32, 1990; and Tohgi, H., et al., A selective reduction of excitatory amino acids in cerebrospinal fluid of patients with Alzheimer type dementia compared with vascular dementia of the Binswanger type., *Neurosci. lett.*, 141, 5-8, 1992).


[0011] Alternatively, a number of papers report an anti-amnesia action of a glycine-site agonist in animal models (Matsuoka N. and Aigner T. G., D-Cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys, *J. Exp. Pharmacol. Ther.*, 278, 891-7, 1996; Ohno M., et al. Intrahippocampal administration of a glycine site antagonist impairs working memory performance of rats. *Eur. J. Pharmacol.*, 253, 183-7, 1994; and Fishkin R.J., et al., D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats., *Behav. Neural. Biol.*, 59, 150-7, 1993). These findings suggest that drugs inhibiting the activity of glycine transporter and thereby activating the function of NMDA receptor are useful as therapeutic agents of dementia, schizophrenia and other cognitive disorders.

[0012] As the glycine transporter inhibitor, WO97/45115 disclosing tertiary amines and WO97/45423 disclosing piperidine derivatives (TROPHIX PHARMACEUTICALS INC.), WO99/34790 disclosing amino acid derivatives and WO99/41227 disclosing tricyclic compounds (ALLELIX NEUROSCIENCE INC.), WO99/4459 and WO99/45011 disclosing piperidine derivatives (JANSSEN PHARMACEUTICA N.V.), and WO00/07978 disclosing aminomethylcarbonate derivatives (AKZO NOBEL N.V.) are reported, other than glycyldodecylamide (GDA). As 1,2,4-triazole derivatives, the following compounds are disclosed: DE4302051 (Dr. Karl Thomae G.m.b.h., platelet aggregation inhibitory activity; *Iran. J. Chem. Chem. Eng.* (1998), 17, 14 (A. Shafiee, et al., antibacterial and antifungal activities), DE3808283 (Boehringer Ingelheim KG., platelet activation factor antagonistic activity), WO97/32873 (Pfizer Research and Development Company N.V., NMDA receptor antagonistic activity), and DD251345 (VEB Chemiekombinat Bitterfeld Ger. Dem. Rep., biocidal activity), *Eur. J. Med. Chem.* (1985), 20, 257 (F. Clemence, et al., analgesic and anti-inflammation activity), *Sci. Pharm.* (1978), 46, 298 (A. A. B. Hazzaa, et al., anti-spasm action). However, there are no reports that these compounds inhibit glycine transporter activity.

[0013] Based on the background described above, the present inventors have made investigations about compounds with potent inhibitory activity of glycine transporter. Consequently, the inventors have found that a specific type of triazole derivative has a potent inhibitory activity of glycine transporter. Thus, the invention has been achieved.

Disclosure of the Invention

[0014] The invention relates to a glycine transporter inhibitor which comprises a triazole derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof as the effective ingredient:



(in the formula, the symbols represent the following meanings; Ring A:

(1) an aromatic carbon ring which may be substituted,

(2) an aliphatic carbon ring which may be substituted and may be condensed with benzene ring or hetero ring,
 (3) a 5-membered hetero ring which may be substituted and contain one or two nitrogen atoms as the hetero atoms composing the ring and may contain one oxygen atom or sulfur atom as a hetero atom other than the nitrogen atoms and may be condensed with benzene ring or

(4) a 6-membered hetero ring which may be substituted and contain one nitrogen atom as a ring atom and may contain one oxygen atom or sulfur atom as a hetero atom other than the nitrogen atom and may be condensed with benzene ring;

Ring B or D may be the same or different and each represents aromatic carbon ring which may be substituted, an aliphatic carbon atom which may be substituted, or a hetero ring which may be substituted.

R: H, halogeno-lower alkyl, aryl which may be substituted, hetero ring which may be substituted, cycloalkyl which may be substituted, or $-\text{[Alk1]}_m\text{-X-[Alk2]}_n\text{-Y-R}^1$

wherein R^1 : H, OH, cyano, aryl which may be substituted, hetero ring which may be substituted, cycloalkyl which may be substituted, or lower alkoxyl;

X: bond, oxygen atom, S(O)_q , or $-\text{N(R}^2\text{)}_-$;

Y: bond, $-\text{C(O)}_-$, $-\text{C(O)-N(R}^3\text{)}_-$, $-\text{Z}_1\text{-Alk3-}$, or $-\text{N(R}^3\text{)-Alk3-C(O)-}$, with the proviso that R^1 represent other than OH and lower alkoxy, when Y is bond;

Alk1 or Alk2 may be the same or different and each represents lower alkylene, lower alkenylene or lower alkynylene; and m or n may be the same or different and each represents 0 or 1 or $m + n = 1$, provided that X represents bond;

Z_1 : S(O)_q , $-\text{N(R}^3\text{)}_-$, $-\text{C(O)}_-$ or $-\text{C(O)-N(R}^3\text{)}_-$;


Alk3: lower alkylene;

R^2 or R^3 : the same or different from each other and each represents H or lower alkyl;

q: 0, 1 or 2 may be)


[0015] Additionally, the invention relates to a pharmaceutical composition containing a glycine transporter inhibitor represented by the general formula (I) as the effective ingredient.

[0016] The invention furthermore relates to a novel triazole derivative represented by the following general formula (Ia) or a salt thereof.



(in the formula, the symbols represent the following meanings; Ring A' :

(1) the group represented by the formula:



(2) naphthalene which may be substituted with one or two substituents selected from the group represented by Rf ,

(3) an aliphatic carbon ring which may be substituted with one or two substituents selected from the group represented by Rf and which may be condensed with benzene ring or hetero ring,

(4) a 5-membered hetero ring which may be substituted with one or two substituents selected from the group represented by Rf and contain one or two nitrogen atoms as the hetero atoms composing the ring and may contain one oxygen atom or sulfur atom as a hetero atom other than the nitrogen atoms and may be condensed with benzene ring; or

(5) a 6-membered hetero ring which may be substituted with one or two substituents selected from the group represented by Rf and which contain one nitrogen atom as the ring atom and may contain one oxygen atom or

sulfur atom as a hetero atom other than the nitrogen atom and may be condensed with benzene ring;

Ring B': benzene or nitrogen-containing monocyclic hetero ring; or

Ring D': benzene or hetero ring, provided that ring A', B' and D' never simultaneously represents benzene ring;

Ra: a halogeno-lower alkyl, a hetero ring which may be substituted, cycloalkyl which may be substituted, or -[Alk1]
m-X-[Alk2]_n-Y-R¹

wherein

R¹: H, OH, cyano, aryl which may be substituted, hetero ring which may be substituted, cycloalkyl which may be substituted, or lower alkoxy;

X: bond, oxygen atom, S(O)_q, or -N(R²)-;

Y: bond, -C(O)-, -C(O)-N(R³)-, -Z₁-Alk3-, or -N(R³)-Alk3-C(O)-, with the proviso that R¹ represent other than OH and lower alkoxy, when Y is bond;

Alk1 or Alk2 may be the same or different and each represents lower alkylene, lower alkenylene, or lower alkynylene;

m or n may be the same or different and each represents 0 or 1 or m + n = 1, provided that X represents bond;

Z₁: S(O)_q, -N(R³)-, -C(O)- or -C(O)-N(R³)-;

Alk3: lower alkynylene;

R² or R³: the same or different from each other and each represents H, or lower alkyl;

Rb: halogen atom, lower alkyl which may be substituted with the following substituents, lower alkynyl, halogeno-lower alkyl, hetero ring, hetero ring-O-, cyano, nitro, halogeno-lower alkyl-O-, lower alkoxy, -O-lower alkylene-N(R³)-lower alkylene-C(O)-O-R⁶, Z₂-R⁶, or Z₃-R⁷, the substituents of the lower alkyl: OH, cyano, lower alkoxy, amino which may be substituted with lower alkyl;

Z₂: S(O)_q, -N(R³)-, -C(O)-, -C(O)-N(R³)-, -N(R³)-C(O)-, -C(O)-S(O)_q-, -N(R³)-S(O)_q-, or -C(O)O-;

Z₃: -N(R³)-, or -N(R³)-C(O)-;

R⁶: H, lower alkyl or aryl;

R⁷: OH, or lower alkoxy;

p: 0 or 1;

q: 0, 1 or 2;


Rc: lower alkyl, or halogen atom;

Rd or Re: the same or different from each other and each represents H, halogen atom, lower alkyl, lower alkoxy, OH, lower alkyl, halogeno-lower alkyl, phenyl, halogeno-lower alkyl-O-, amino which may be substituted with lower alkyl or -NR⁸C(O)-R⁹;

R⁸ or R⁹: the same or different from each other and each represents H, or lower alkyl;

Rf: a group represented by Rb, oxo group, or aryl, with the proviso that Rd represents other than H, when the ring A' represents benzene substituted with lower alkoxy and the ring B' represents benzene.

[0017] Additionally, the invention provides a novel triazole derivative represented by the following general formula (lb) or a salt thereof.



(in the formula, the symbols represent the following meanings:

Ra, Rc or p: the same group as formula (la) described in the claim 3;

Rb': halogen atom, lower alkyl which may be substituted with the following substituents, halogeno-lower alkyl, hetero ring, hetero ring-O-, cyano, nitro, halogeno-lower alkyl-O-, lower alkoxy, -O-lower alkylene-N(R³)-lower alkylene-C(O)-O-R⁶, -N(R³)-R⁷, Z₂'-R⁶, or Z₃-R⁷;

the substituents of the lower alkyl: OH, cyano, lower alkoxy, amino which may be substituted with lower alkyl;

Z₂': S(O)_q, -C(O)-, -C(O)-N(R³)-, -N(R³)-C(O)-, -C(O)-S(O)_q-, -N(R³)-S(O)_q-, -C(O)O-;

R³, Z₃, R⁶, R⁷ or q: the same group as formula (la) described in the claim 3;

Rd': H, lower alkoxy, OH or lower alkyl;

Re': H, halogen atom, lower alkoxy, halogeno-lower alkyl, halogeno-lower alkyl-O-, or NR⁸C(O)-R⁹;

R⁸ or R⁹ : the same group as formula (Ia) described in the claim 3;

5 with the proviso that,

(1). at least one of Rd' or Re' represents a group other than H, when Ra is lower alkyl, p = 0:

10 Rb' represents lower alkyl, lower alkoxy or halogen atom; or Rd' represents a group except for lower alkyl, provided that Re' is H;

(2). Rb' represents a group other than lower alkyl or lower alkoxy, when Ra represents α -styryl and Rd' and Re' represent H and p = 0;

15 (3). Rb' represents a group other than lower alkyl, when Ra represents 2-furyl and Rd' and Re' represent H and p = 0.)

[0018] The invention relates to a triazole derivative represented by the general formula (Ia) or a salt thereof, wherein the ring B' represents nitrogen-containing monocyclic hetero ring; the ring D' is benzene ring; Rf is halogen atom, lower alkyl, lower alkoxy, aryl, cyano, carbamoyl or oxo group; more preferably, the ring B' is pyridine ring; the ring D' is benzene ring; and the ring A' is 2,1,3-benzooxadiazole, or benzene substituted with one or two substituents selected from lower alkyl, halogen atom or cyano; and

most preferably, the triazole derivative is 5-[4-(2,6-difluorophenyl)-5-isopropyl-4H-1,2,4-triazol-3-yl]-2-phenylpyridine; 4-[3-isopropyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzooxadiazole;

3-[3-(3-methoxypropyl)-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2-methylbenzonitrile;

25 3-[3-ethyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2-methylbenzonitrile;

2-[3-[N-(2-methoxyethyl)-N-methylamino]-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]benzonitrile;

4-(2,1,3-benzooxadiazol-4-yl)-N-(2-methoxyethyl)-N-methyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-3-ylamine or a salt thereof.

30 Additionally, the invention relates to a pharmaceutical composition which comprises the triazole derivative of the general formula (Ia) or (Ib) as an active ingredient.

[0019] The triazole derivative in accordance with the invention will further be described.

[0020] The substituent as described in the phrase 'which may be substituted' specifically includes those described below, unless otherwise stated.

35 [0021] Above mentioned substituted groups are represented by Rb', Rf, Rd and Re, hetero ring groups bound via nitrogen atom, and the like.

[0022] Herein, the term 'lower' in the specification represents linear or branched hydrocarbon chain with one to 6 carbon atoms.

[0023] Thus, the term 'lower alkyl' means monovalent saturated hydrocarbon, linear or branched, specifically including for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, isopentyl and the like.

40 [0024] The term 'lower alkynyl' represents monovalent, linear or branched unsaturated hydrocarbon with one or more triple bonds with 2 to 6 carbon atoms and with both the termini being of free atomic valence and specifically includes ethynyl, 1-propionyl and the like.

[0025] The term 'lower alkylene' represents the saturated hydrocarbon of divalence and with both the termini being of free atomic valence.

45 [0026] The term 'lower alkenylene' represents divalent, linear or branched unsaturated hydrocarbon with one or more double bonds with 2 to 6 carbon atoms and with both the termini being of free atomic valence and specifically includes vinylene, propenylene and the like.

[0027] The term 'lower alkynylene' means divalent, linear or branched unsaturated hydrocarbon with one or more triple bonds with 2 to 6 carbon atoms and with both the termini being of free atomic valence.

50 [0028] The term 'lower alkoxy' specifically includes for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, t-butoxy, pentyloxy, hexyloxy, and isohexyloxy and the like.

[0029] 'Halogen atom' includes fluorine, chlorine, bromine and iodine.

[0030] 'Halogeno-lower alkyl' means the lower alkyl substituted with one or more halogen atoms, which is preferably trifluoromethyl and trifluoroethyl.

55 [0031] 'Aromatic carbon ring' includes benzene and naphthalene, while the monovalent aromatic carbon ring group is expressed as 'aryl'.

[0032] 'Aliphatic carbon ring' means 3- to 8-membered monocyclic saturated hydrocarbon ring, while the monovalent group thereof is expressed as 'cycloalkyl'. Preferably, the 'aliphatic carbon ring' is cyclopropyl, cyclopentyl and cy-

clohexyl.

[0033] 'Aliphatic carbon ring which may be condensed with benzene ring' means an aliphatic carbon ring condensed with benzene ring and is bound via the carbon atom on the aliphatic carbon ring to other groups. Preferably, the ring is indane and 1,2,3,4-tetrahydronaphthalene.

[0034] 'Aliphatic carbon ring which may be condensed with hetero ring' means the aliphatic carbon ring condensed with the following hetero ring and is bound via the carbon atom on the aliphatic carbon ring to other groups. Preferably, the ring is 5,6,7,8-tetrahydroquinoline.

[0035] 'Hetero ring' means aromatic hetero ring, saturated hetero ring and unsaturated hetero ring.

[0036] 'Aromatic hetero ring' means 5- or 6-membered monocyclic or condensed heteroaryl containing one to 3 hetero atoms selected from nitrogen atom, oxygen atom or sulfur atom and the aromatic hetero ring is bound via the carbon atom or nitrogen atom in the ring to other groups. Preferably, the aromatic hetero ring includes furan, pyrrole, thiophen, pyrazole, thiazole, imidazole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline and quinoxaline rings and the like.

[0037] Herein, the hetero ring represented by Rb or Rb' means those bound via the carbon atom in the ring to benzene ring.

[0038] 'Saturated hetero ring' means 5- or 6-membered, saturated hetero ring containing one to 3 hetero atoms selected from nitrogen atom, oxygen atom or sulfur atom and is bound via the carbon atom or nitrogen atom in the ring to other groups. Preferably, the saturated hetero ring includes pyrrolidine, piperidine, piperazine and morpholine rings and the like.

[0039] 'Unsaturated hetero ring' means 5- or 6-membered, unsaturated hetero ring containing double bond in the hetero ring, except for aromatic hetero ring.

[0040] 'Nitrogen-containing monocyclic hetero ring' means saturated or aromatic 5- or 6-membered monocyclic hetero ring which essentially contains one or more nitrogen atoms as the constitutional elements of the ring and may contain one to 3 hetero atoms selected from oxygen atom or sulfur atom as other hetero atoms, in the 'hetero ring' described above and the 'nitrogen-containing monocyclic hetero ring' is bound via the carbon atom or nitrogen atom in the ring to other groups. Preferably, the nitrogen-containing hetero atom is pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, furazan, pyridine, pyrazine, pyrimidine, pyridazine, pyrrolidine, piperidine, piperazine, morpholine and the like. More preferably, the nitrogen-containing monocyclic hetero ring is 5- or 6-membered monocyclic hetero ring where the hetero atom as the constitutional element of the ring is only nitrogen atom and contains one to 3 nitrogen atoms.

[0041] '5-membered hetero ring which may contain one or 2 nitrogen atoms as the hetero atoms composing the ring and may contain one oxygen atom or sulfur atom as the hetero atom other than the nitrogen atoms and which may be condensed with benzene ring' as represented by the item (4) for the ring A means, among the hetero rings, a 5-membered hetero ring which may contain 2 or less nitrogen atoms as the constitutional atoms of the ring and may contain one oxygen atom or nitrogen atom other than the atoms, as well as the 5-membered hetero ring in condensation with benzene ring.

[0042] The 5-membered hetero ring includes thiazole, furan, pyrrole, imidazole, pyrazole, furazan, thiadiazole, pyrazolidine, benzoimidazole, benzofuran, benzooxadiazole, benzothiadiazole, indole, isoindole, indazole and the like.

[0043] '6-membered hetero ring which may contain one nitrogen atom as the ring atom and may contain one oxygen atom or sulfur atom as a hetero atom other than nitrogen atom and which may be condensed with benzene ring' as represented by the item (4) for the ring A means, among the hetero rings, a 6-membered hetero ring which may contain nitrogen atom within one in number as the ring-composing atom and may contain one oxygen atom or sulfur atom other than the atom described above-mentioned the hetero ring, as well as the 6-membered hetero ring in condensation with benzene ring.

[0044] The 6-membered hetero ring includes morpholine, pyridine, piperidine, quinoline, isoquinoline, 1,2-dihydroisoquinoline and 1,2,3,4-tetrahydroisoquinoline.

[0045] The compound for use as the effective ingredient of the pharmaceutical composition of the invention can sometimes form a salt with an inorganic acid or an organic acid. The salt thereof has an action to inhibit the activity of glycine transporter. The preferable salt includes for example salts thereof with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid or phosphoric acid or the like; salts thereof with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, carbonic acid, glutamic acid, aspartic acid, methanesulfonic acid or ethanesulfonic acid or the like; salts thereof with inorganic bases such as sodium, potassium, magnesium, calcium or aluminum or the like; salts thereof with organic bases such as methylamine, ethylamine or ethanolamine or the like; and salts thereof with basic amino acids such as lysine or ornithine or the like. Additionally, the compound can form tertiary ammonium salt when the compound reacts with lower alkyl halide, lower alkyl triflate, lower alkyl tosylate or benzyl halide or the like. As such tertiary ammonium salt, the salt of the compound with methyl iodide or benzyl chloride or the like is preferable.

[0046] The compound for use as the effective ingredient in the pharmaceutical composition of the invention includes

optical isomers based on the asymmetric carbon atoms, geometric isomers based on the double bonds or cyclohexane ring, and atropoisomers occurring due to the inhibition of the rotation around a certain single bond. When two or more asymmetric carbon atoms are present, furthermore, the compound includes diastereomers. These various types of isomers isolated and mixtures of these isomers are also encompassed within the scope of the invention. Furthermore, the compound of the present invention includes hydrates, various solvates and tautomeric isomers. Still further, the compound for use as the effective ingredient of the inventive pharmaceutical composition includes compounds of crystal polymorphism. All these crystal forms are also encompassed within the scope of the compound for use as the effective ingredient of the pharmaceutical composition of the invention.

[0047] Further, the compound of the present invention includes pharmacologically acceptable prodrugs. The group forming the pharmaceutically acceptable prodrugs of the compound of the present invention includes the group described in Prog. Med. 5; 2157-2161 (1985) and the group described in "Development of pharmaceutical products", Vol. 7, Molecular designing, pp. 163 - 198, Hirokawa Shoten, 1990. More specifically, the group can be converted to the primary amine, secondary amine, OH or COOH group, through hydrolysis or solvated decomposition or under physiological conditions and include for example lower alkylene -COOR (R represents H or lower alkyl; the same is true hereinbelow) which may be substituted with -OCO-, lower alkenylene-COOR which may be substituted with -OCO-, aryl which may be substituted with -OCO-, -OCO-lower alkylene-O-lower alkylene-COOR, -OCO-COR, lower alkyl which may be substituted with -OCO-, lower alkylene-COOR which may be substituted with -OSO₂-, -O-futazyl, 5-methyl-1,3-dioxolen-2-on-4-yl-methyloxy.

[0048] Herein, the following compounds are included among preferable examples of known compounds encompassed within the invention of use. For example, the following compounds among the compounds disclosed in Japanese Patent Laid-open No. 2000-63363 are included:

2-[3-(biphenyl-4-yl)-5-methyl-4H-1,2,4-triazol-4-yl]phenol
 3-(biphenyl-4-yl)-4-(2-ethoxyphenyl)-5-methyl-4H-1,2,4-triazole,
 3-(biphenyl-4-yl)-5-methyl-4-(2-propoxyphenyl)-4H-1,2,4-triazole,
 3-(biphenyl-4-yl)-5-ethyl-4-(2-methoxyphenyl)-4H-1,2,4-triazole,
 4-(2-methoxyphenyl)-3-methyl-5-(2'-methylbiphenyl-4-yl)-4H-1,2,4-triazole and
 3-(biphenyl-4-yl)-4-(2-iodophenyl)-5-methyl-4H-1,2,4-triazole.

[0049] Other than those described above, for example, 3-(biphenyl-4-yl)-5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazole (LTPBP42, CD-ROM catalog 1996), 3-(biphenyl-4-yl)-4-(2-methoxyphenyl)-5-methyl-4H-1,2,4-triazole (LTPBP20, CD-ROM catalog 1996) commercially available from LaboTest Co. (Freiberg, Germany) and the like are also included.

(Production Process)


[0050] The production process of the compound in accordance with the invention is now described below.

[0051] The objective 3,4,5-tri-substituted-1,2,4-triazole derivative can be synthetically prepared by the following processes. But the production process of the compound of the present invention is not limited to them.


Production Processes Nos. 1 to 3

[0052]


Production Processes No. 1



Production Processes No. 2



Production Processes No. 3



(In the formula, L^1 represents oxygen atom or sulfur atom; R^{10} represents lower alkyl and the like. The remaining symbols represent the same as described above. The same is true hereinbelow.)

[0053] At the production processes Nos. 1 to 3, the objective 3,4,5-tri-substituted-1,2,4-triazole can be prepared in an almost similar fashion to the method described for example in the unexamined publication (Japanese Patent unexamined publication No. 2000-63363).

[0054] According to the production process No. 1, the objective 3,4,5-tri-substituted 1,2,4-triazole derivative can be prepared by subjecting acid hydrazide (1) commercially available or possibly prepared by an almost similar method to the method described in Japanese Patent unexamined publication No. 2000-63363 and the compound (2) to nucleophilic substitution reaction and dehydration cyclarization reaction.


[0055] According to the production process No. 2, the compound of the present invention can be prepared by subjecting the compound (4) possibly prepared by an almost similar method to the method described in Japanese Patent Laid-open No. 2000-63363 and acid hydrazide (5) to nucleophilic substitution reaction and dehydration cyclarization reaction.

[0056] According to the production process No. 3, the compound of the present invention can be prepared by subjecting 1,3,4-oxadiazole (7) prepared by dehydration cyclarization reaction of diacylhydrazine (6) to reaction with appropriate amine derivative (8).


Production Processes Nos. 4 and 5

[0057]

Production Processes No. 4



Production Processes No. 5



(In the formula, L^2 and L^3 represent halogen, alkyl- or aryl-sulfonyloxy such as trifluoromethanesulfonyloxy, and phosphoryloxy substituted with lower alkoxy group; M^1 and M^2 represent metals such as magnesium, zinc, boron and tin and the like; M^2-Q represents organic metal compounds and metal halides, for example, described in the reference edited by Tsuji Jiro (Senikinzoku Ga Hiraku Yukigosei, p.25 - p. 37 (1997)) and the like; and B'' represents an aromatic carbon ring or aromatic hetero ring; and D'' represents an aromatic carbon ring or aromatic hetero ring.)

[0058] The 1,2,4-triazole derivative (11) with aromatic rings as the rings B'' and D'' can be synthetically prepared, using the following production processes Nos. 4 and 5, in addition to the production processes Nos. 1, 2 and 3.

[0059] The production process No. 4 is a production process, utilizing the cross coupling reaction between compound of the present invention (9) with halogen or alkylsulfonyloxy as the substituent L^2 on the aryl or heteroaryl ring B'' and appropriate aryl metal or heteroaryl metal compound (10). Additionally, the production process No. 5 is a production process, utilizing the cross coupling reaction between aryl metal or heteroaryl metal compound (13) prepared from 1,2,4-triazole derivative (9) and aryl or heteroaryl compound (14) with appropriate halogen or alkylsulfonyl group.

[0060] The cross coupling reaction in the production processes Nos. 4 and 5 can be performed in an appropriate solvent such as tetrahydrofuran and N,N-dimethylformamide in the presence of palladium compound or nickel compound (for example, tetrakis(triphenylphosphine) palladium) and in the presence or absence of a base, if necessary, under cooling or heating, using an aryl metal or heteroaryl metal compound (10 or 13) containing magnesium, zinc, boron and tin and the like and an aryl or heteroaryl compound (9 or 14) with an appropriate halogen or an alkylsulfonyloxy group as the raw materials.

Production Process No. 6


[0061]

5

10

15

20



(In the formula, L^5 represents a leaving group such as halogen and the like and X represents NR^2 or oxygen atom.)

25

[0062] The 1,2,4-triazole derivative (19) with a substituent binding via nitrogen atom or oxygen atom at position 5 can also be prepared by converting the 1,2,4-triazole derivative (16) synthetically prepared by the production process No. 2 into the compound (17), for example, according to the method described by Walser, et al. (Journal of Heterocyclic Chemistry, 12, 717 (1975)) and subjecting amine or alcohol derivative (18) to reaction without any solvent or in an appropriate solvent (for example, xylene) in the presence or absence of an appropriate base at 50 to 200 °C for 2 to 72 hours.

30

Production process No. 7


[0063]

35

40

45

50



55

(In the formula, the base represents sodium hydroxide and the like; L^4 represents a leaving group such as halogen and the like.)

[0064] The 1,2,4-triazole derivative (24) with a substituent binding via sulfur atom at the position 5 can also be prepared, using acid hydrazide (1) commercially available or prepared by a similar method to the method described in

Japanese Patent unexamined publication No. 2000-63363 as a raw material, for example according to the method of Maxwell, et al. (Journal of Medicinal Chemistry, 27, 1565 (1984)).

[0065] As described above, the compound of the present invention includes isomers such as racemic compounds, optically active compounds and diastereomers and the like, being present singly or in mixture. The racemic compounds can be introduced into stereochemically pure isomers, using appropriate raw material compounds or by general racemic resolution processes (for example, a process of optical resolution, comprising introducing the raw material compounds into diastereomer salts with general optically active acids (tartaric acid, etc.)). Additionally, diastereomer mixtures can be separated by general methods, for example fractional crystallization or chromatography or the like.

Pharmacological tests

[0066] The pharmacological actions of the compound of the present invention are described hereinbelow.

[0067] The action of the compound of the present invention to inhibit the activity of the glycine transporter was verified by the following test methods.

1. Action of inhibiting glycine transporter

(Cell culture)

[0068] C6 glioma cell expressing GLYT1 subtype of the glycine transporter (see Gomeza-J., Zafra-F., Olivares-L., Gimenez-C., Aragon-C., Regulation by phorbol esters of the glycine transporter (GLYT1) in glioblastoma cells., Biochim-Biophys-Acta., 1233, 41-46 (1995)) was used.

[0069] C6 glioma cell (American Type Culture Collection) was cultured in DMEM containing 10% fetal bovine serum, 100 units/ml penicillin G and 0.1 mg/ml streptomycin sulfate in a CO₂ incubator under conditions of 5% CO₂ and 37 °C.

([³H]-glycine uptake assay)

[0070] [³H]-glycine uptake was performed by the method of Gomeza, et al.

[0071] C6 glioma cells were plated out at a concentration of 2×10⁴ cells/well in a 96-well plate (Culturplate, Packard Co.), for culturing for 2 days. Subsequently, [³H]-glycine uptake was tested. The cell was rinsed once in a buffer (150 mM NaCl, 5 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 10 mM glucose, 5 mM L-alanine, 10 mM Hepes-Na, pH 7.4), followed by subsequent addition of the buffer, for incubation at 37 °C for 10 minutes.

[0072] After incubation, the buffer was exchanged to a reaction buffer including [³H]-glycine (about 0.2 μM, 41 Ci/mmol, New England Nuclear) and a compound to be assessed, for incubation at 37 °C for another 20 minutes. After 20-min reaction, the reaction mixture was rinsed in ice-cold PBS (phosphate buffered saline). The cell was dissolved in 0.1N NaOH solution, to assay the radioactivity incorporated with a liquid scintillation counter. The specific incorporation was defined as a portion substituted with 3 mM sarcosine in the total incorporation. The test compound was assessed by determining the incorporation-inhibiting ratio of the specific incorporation.

[0073] Consequently, the compound of the present invention was verified to have an action to inhibit [³H]-glycine incorporation.

Test compound	GLYT-inhibiting activity IC ₅₀ (μM)
Compound 1	1.0
Compound 2	4.6
Compound 3	0.35
Production Example 1	0.36
Example 1	0.14
Example 2	0.10
Example 5	0.41
Example 6	0.26
Example 8	0.25
Example 9	0.33
Example 10	0.20
Example 112	1.0

(continued)

Test compound	GLYT-inhibiting activity IC50(μM)
Example 157	1.5
Example 202	1.6
Example 236	0.94
Example 256	0.086
Example 279	4.6

Compound 1:

[0074] 3-(biphenyl-4-yl)-4-(2-methoxyphenyl)-5-methyl-4H-1,2,4-triazole (Japanese Patent unexamined publication No. 2000-63363; Example 33)

Compound 2:

[0075] 3-(biphenyl-4-yl)-5-(furan-2-yl)-4-phenyl-4H-1,2,4-triazole (LTPBP42 CD-ROM catalog 1996 of LaboTest Co. (Freiburg, Germany))

Compound 3:

[0076] 3-(biphenyl-4-yl)-5-ethyl-4-(2-methoxyphenyl)-4H-1,2,4-triazole (Japanese Patent unexamined publication No. 2000-63363; Example 23)

2. Experimental method of (+)-HA966-induced enhancement of activity in mouse

[0077] the method reported previously (J. Neural Transm., 97: 175-185, 1994) was used for carrying out the experiment with modification.

Animal: male ICR mouse (Nippon SLC; age 5 to 7 weeks)

Chemical drug : reserpine (Apoplone Injection of 1 mg/ml;

manufactured by Daiichi Pharmaceuticals Co., Ltd.), (+)-HA966 (Proc. Nat. Acad. Sci. U.S.A., 87, 347-351, 1990), α -methyl-para-tyrosine methyl ester (Sigma, Inc.).

Experimental apparatus: Supermex (Muromachi Machine)

Experimental method

[0078]

(1) Pharmaceutical drug-treated groups were defined as follows. (16 mice per one group were used for the experiment).

(ACSF + Vehicle) group

{(+)-HA966 80 μg/mouse icv + Vehicle} group

{(+)-HA966 80 μg/mouse icv + test compound} group

(2) 19 hours before (+)-HA966 administration, reserpine (10 mg/kg) was dosed intraperitoneally.

(3) 0.5 hour before (+)-HA966 administration,

α -methyl-para-tyrosine methyl ester (250 mg/kg) was intraperitoneally administered.

(4) 20 minutes before (+)-HA966 administration, a test compound was orally given.

(5) (+)-HA966 was acutely administered bilaterally into the lateral ventricle (with free hands using 2-step needle); immediately thereafter, each animal was placed in the measuring cage of an activity measurement apparatus.

(6) Immediately thereafter, the activity per one hour was measured.

(7) The integral value of the activity per one hour was selected as the data. The effect was determined as follows. The enhancement of the activity due to (+)-HA966 {difference between ((+)-HA966 + Vehicle) administration group and (ACSF + Vehicle) administration group} was defined as 100 %. And the activity in a pharmaceutical drug-treated group {difference between ((+)-HA966 + test compound) administration group and (ACSF + test compound) administration group} was normalized. It was calculated by following formula. When the normalized activity was

below 50 %, the test compound was judged to have the effect.

[0079] The formula used for standardization

$$\frac{\{\text{activity of ((+)-HA966 + test compound) administration group} - \text{activity of (ACSF + test compound) administration group}\} + \{\text{activity of ((+)-HA966 + Vehicle) administration group} - \text{activity of (ACSF + Vehicle) administration group}\} \times 100(\%)}$$

[0080] When the compound shown in the Production Example 1 was orally given at 10 mg/kg, the activity was at 43 %.

3. (+)-HA966-induced learning disability (mouse passive avoidance test)

[0081] Animal: male ddY mouse (Nippon SLC; age 7 to 9 weeks at training) was used. 16 to 32 animals were used per one group.

<Experimental procedures>

Preparation of pharmaceutical drugs

[0082]

(1) A test compound for oral administration was suspended in aqueous 0.5 % methyl cellulose solution, and for intraperitoneal administration was suspended in solution dissolved 0.5 % of methyl cellulose solution in saline (hereinafter referred to as 0.5 % methyl cellulose solution). The administration volume was 10 ml per 1 kg · body weight. As a placebo of the test compound, 10 ml per 1 kg · body weight of aqueous 0.5 % methyl cellulose solution for oral administration and 10 ml of aqueous 0.5 % methyl cellulose solution (herein referred to as vehicle) for intraperitoneal administration (herein referred to as vehicle) was administered.

(2)(+)-HA966 was dissolved in artificial cerebrospinal fluid (ACSF). The administration volume was 4 µl per one mouse. As a vehicle of (+)-HA966, 4 µl of ACSF was dosed per one mouse.

Intracerebral cannula apparatus

[0083] 7 to 14 days before the initiation of training, a cannula for intracerebroventricular administration was implanted to the animals under anesthesia.

Training

[0084]

(1) On day 1 at the learning experiment, the mice were acclimated in an experimental room for one hour or longer.

(2) A test compound or the vehicle was orally or intraperitoneally given.

(3) 20 minutes thereafter, (+)-HA966 was administered at 60 µg intracerebroventriculally.

(4) 15 minutes after the dosing of (+)-HA966, the each mouse was placed in the bright room of the experimental apparatus of the passive avoidance reaction test, where the mouse was left for 30 seconds. Subsequently, the guillotine door was opened. When the mice entered in the dark room, the mice were exposed to an electric shock at an intensity of 60V and a delay of 1 sec for a duration of 2 sec. When the mice thus returned to the bright room, the guillotine door was closed. Then, the mice were left in the bright room for 30 seconds.

(5) The mice were taken out to be back to the home cage.

(6) After the termination of the training, the mice were left to stand in the experimental room and were then back to the feeding room.

Test (24 hours after the training)

[0085]

- 5 (1) The animals were left in the experimental room for one hour or longer.
- (2) After the mice were placed in the bright room and left for 30 seconds, the guillotine door was opened.
- (3) The time (step-through latency) required for the mice to cross the sensor of the dark room from the opening of the guillotine door was counted. The longest time for the measurement was 300 seconds.
- 10 (4) The step-through latency was adopted as an indicator of learning ability. The learning disability due to (+)-HA966 was compared between the two groups, namely (ACSF + Vehicle) group and {(+)-HA966 + Vehicle} group by the Wilcoxon rank sum test. The action of an assessment compound on the improvement of leaning disability was compared between many groups, namely {(+)-HA966+Vehicle} group and {(+)-HA966+assessment compounds} groups by the two-tailed Steel test. A significance was determined at $p < 0.05$.

- 15 **[0086]** The compound shown in the Production Example 1 as dosed intraperitoneally was at the minimum effective dose of 3 mg/kg.

4. Electric convulsion shock (ECS)-induced learning disability (mouse passive avoidance test)

- 20 **[0087]** With reference to the previous report (Eur J Pharmacology, 321; 273-278, 1997), assessment was done as follows. Animal: male ddY mouse (Nippon SLC; age 5 weeks at training) was used. 16 animals were used per one group.

<Experimental procedures>

25 Preparation of chemical agents

- 30 **[0088]** A test compound for oral administration was suspended in aqueous 0.5 % methyl cellulose solution, and for intraperitoneal administration was suspended in solution dissolved 0.5 % of methyl cellulose solution in saline. The dose administered was 10 ml per 1 kg • body weight. As a placebo of the test compound, 10 ml of aqueous 0.5 % methyl cellulose solution for oral administration and 10 ml of 0.5 % methyl cellulose solution in saline for intraperitoneal administration (herein referred to as vehicle) was administered.

Training

35 **[0089]**

- (1) On day 1 at the experiment, the mice were left in an experimental chamber for one hour or longer.
- (2) The mice were placed in the bright room of the experimental apparatus of the passive avoidance test, where the mice were left to stand for 30 seconds. Subsequently, the guillotine door was opened. When the mice entered
- 40 in the dark room, the mice were exposed to an electric shock at an intensity of 60V and a delay of 1 sec for a duration of 2 sec. When the mice thus returned to the bright room, the guillotine door was closed. Then, the mice were left to stand in the bright room for 30 seconds.
- (3) The mice were taken out. An electrode was attached on both the ears immediately (within one minute), to give ECS (electric convulsion shock).
- 45 (4) A test compound was administered orally or intraperitoneally.
- (5) The mice were back to the home cage.
- (6) After the termination of the training, the mice were left in the experimental room for 60 minutes or longer and were then back to the feeding room.

50 Test (24 hours after the training)

[0090]

- 55 (1) The animals were left in the experimental room for one hour or longer.
- (2) After the mice were placed in the bright room and left for 30 seconds, the guillotine door was opened.
- (3) The time (step-through latency) required for the mice to cross the sensor of the dark room from the opening of the guillotine door was counted. The longest time for the measurement was 600 seconds.
- (4) The step-through latency was adopted as an indicator of learning ability. The learning disability due to ECS

was compared between the two groups, namely (ECS-no load + Vehicle) group and (ECS load + Vehicle) group by the Wilcoxon rank sum test. The action of a test compound on the improvement of leaning disability was compared between many groups, namely (ECS load + Vehicle) group and (ECS load + assessment) compounds groups by the two-tailed Steel test. A significance was determined at $p < 0.05$.

[0091] The compound shown in the Production Example 1 as dosed intraperitoneally was at the minimum effective dose of 10 mg/kg.

5. Action of assessment compound on learning disability in aged rat (water maze task).

[Experimental method]

[0092] The experimental protocol was defined as follows, with reference to the method of Baxter M., et al. (Neurobiol. Aging 15, 207-213, 1994).

[0093] Male F344 rats (Nippon Charles River) of age 24 ± 1 months (aged rats) were used at the experiment. Water (25 °C) was charged in a circle pool of a diameter of 130 cm and a height of 40 cm to a depth of 25 cm, in which a plastic platform of a diameter of 10 cm and a height of 24 cm was arranged to a depth of about 1 cm below the water surface. During the test, water in the pool was made completely opaque, using black ink. Handling: 3-min handling was carried out twice for all the rats, prior to the experiment.

Shaping : a platform was placed in an alley with a 15-cm width, a 35-cm height (from the water surface) and a 100-cm length. Black opaque water was charged therein so as to place the platform to a depth of about 1 cm below the water surface. The platform was placed the end of the alley. Each rat was placed at a specific place in the alley, allowed to reach the platform. Three successive start locations, each transfer away from the platform, were used; (a) on the platform, (b) with forepaws on the platform, (c) approximately 25 cm from the platform. After the rat climbs on the platform, the rat is retained there for about 10 seconds.

Straight swim: rats are placed on the end of the alley (the opposite side of the platform), to allow the rats to swim three times. When the rats reach the platform, the rats are retained on the platform for about 10 seconds. The latency until the rats reach the platform is recorded.

Acquisition task: rats are gently placed in water, while the rats face on the poolwall so as to subject the rats to acquisition trial at 5 times/day at maximum for the longest duration of 8 days. The latency until the rats reach the platform is recorded with a color video tracking system (Compact VAS) on a computer system. The duration per one trial is set to 60 seconds at maximum. When the rats cannot find the platform within 60 seconds, the experimental person allows the rats to climb the platform. The rats are retained on the platform within about 10 seconds. The trial interval is set to about 2 minutes. The start position (at 7 sites) should be changed every trial in a random manner. For the acquisition trial, 40 trials in total are carried out at maximum. On the first day, the rats are allowed to swim with no dosing of any drug, so as to group the rats evenly on the basis of the latency period. Thereafter, a test compound or the vehicle is dosed for 7 days, to measure the latency period.

Transfer task: about 4 hours after the last trial, 50-sec transfer task is conducted in the absence of platform.

Swim time on the targeted quadrant (quadrant of the pool where the platform was present at acquisition task) was measured. Treatment with pharmaceutical drug: a test compound is suspended in 0.5 % MC physiological saline. The pharmaceutical drug and the vehicle of 1 mg/kg were administered intraperitoneally 30 minutes prior to the training. No administration prior to the transfer task.

[0094] Using the latency at the acquisition task and the time period in which the rats are retained in the target quadrant of the transfer task as markers, the difference between the test compound and the vehicle is compared by two-way ANOVA or Student t-test.

[0095] The efficacy of the compound of present invention on the learning impairment in aged rats can be verified using the water maze

[0096] Additionally, the efficacy of the compound of the present invention on the learning impairment in aged rats can be verified, using as the object recognition test, as shown in for example the previous report (Pharmacological Research, 36(6); 463-469, 1997).

[0097] A pharmaceutical composition containing one or two or more types of the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof or hydrate thereof as the effective ingredient can be prepared into tablets, powders, fine granules, granules, capsules, pills, liquids, injections, suppositories, ointments, and paps and the like, using carriers and excipients for general use for formulation, and other additives. The resulting formulations are orally or parenterally given.

[0098] The clinical dose of the compound of the present invention to humans is appropriately determined, depending on the symptom, age, sex and body weight of an individual patient, to which the compound of the present invention is applied. Generally, the compound of the present invention is orally given at 0.1 to 500 mg per one adult per day in one

portion or divided portions. Because the dose varies under various conditions, a dose below the range of the dose may sometimes be sufficient.

[0099] As the solid composition for oral administration in accordance with the invention, tablets, powders and granules are used. For such solid composition, one or more active substances are mixed with at least one inactive diluent, for example lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, metasilicate aluminate magnesium and the like.

[0100] According to general methods, the composition may satisfactorily contain additives other than inactive diluents, for example lubricants such as magnesium stearate, disintegrators such as cellulose calcium glycolate, stabilizers such as lactose, solubilization or dissolution-auxiliary agents such as glutamic acid or aspartic acid. If necessary, the tablets or pills may be coated with films of substances dissolvable in stomach or intestine, such as sucrose, gelatin, hydroxypropyl cellulose and hydroxypropylmethyl cellulose phthalate and the like.

[0101] The liquid composition for oral dosing contains pharmaceutically acceptable emulsifiers, solubilizers, suspending agents, syrups, and elixirs and the like and contains inactive diluents for general use, for example distilled water and ethyl alcohol. The composition may satisfactorily contain auxiliary agents such as solubilization- or dissolution-auxiliary agents, moisturizers and suspending agents, sweeteners, flavoring agents, aromatic agents and preservatives.

[0102] The injections for parenteral dosing encompass aseptic, aqueous or non-aqueous solubilizers, suspending agents and emulsifiers. The diluents of aqueous solubilizers and suspending agents include for example distilled water for injections and physiological saline. Water-insoluble solubilizers and suspending agents include for example propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethyl alcohol, surfactants such as polysorbate 80 (trade name). Such composition may satisfactorily contain additives including isotonic agents, preservatives, moisturizers, emulsifiers, dispersants, stabilizers (for example, lactose), and solubilization- and dissolution-auxiliary agents (for example, glutamic acid and aspartic acid). These may be sterilized by filtration through for example filter with bacteria retained thereon, blending with sterilizers or irradiation. These may be prepared into aseptic solid compositions. The resulting aseptic compositions are used, after dissolution in aseptic water or aseptic solvents for injections prior to use.

Examples

[0103] As to the novel compound of the invention, the invention is now described in more detail in the following Production Examples and Examples. Herein, the invention is not limited to these compounds alone. Further, the raw materials for use in accordance with the invention are described in Reference Examples, in case that the raw materials are novel.

(Reference Example 1)

[0104] N-(2-Fluorophenyl)-2-methylthiopropionimide methyl ester (1) 2-Fluoroaniline (5.07 g) and triethylamine (9.54 ml) were dissolved in tetrahydrofuran (50 ml), followed by addition of a solution of isobutyryl chloride (5.02 ml) in tetrahydrofuran (20 ml) under ice cooling, and stirred at ambient temperature for 4 hours. After the reaction solution was concentrated under reduced pressure, water (200 ml) was added to the resulting residue, and stirred at ambient temperature for one hour. The resulting solid was filtered and washed with water, to afford N-(2-fluorophenyl)isobutylamide in pale yellow solid (7.08 g, 86 %). The physicochemical values are as follows.

¹H-NMR (CDCl₃) δ: 1.28 (6H, d, J = 6.8 Hz), 2.50 - 2.64 (1H, m), 6.99 - 7.15 (3H, m), 7.37 (1H, brs), 8.32 - 8.38 (1H, m). (2) N-(2-Fluorophenyl)isobutylamide (7.08 g) was dissolved in toluene (90 ml), followed by addition of the Lawesson reagent (8.15 g), and refluxed under heating for one hour. After the reaction solution was cooled to ambient temperature, the solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: n-hexane/ethyl acetate=9/1), to afford N-(2-fluorophenyl)thioisobutylamide as yellow oil (7.74 g, quantitative). The physico-chemical values are as follows.

¹H-NMR (CDCl₃) δ: 1.37 (6H, d, J = 6.8 Hz), 2.94 - 3.08 (1H, m), 7.11 - 7.25 (3H, m), 8.53 - 8.65 (2H, m).

(3) N-(2-Fluorophenyl)thioisobutylamide (7.71 g) was dissolved in acetonitrile (150 ml), followed by addition of potassium carbonate (16.2 g) and methyl iodide (7.30 ml), and stirred at 50 °C for 30 minutes. After the reaction solution was cooled to ambient temperature, the resulting solution was concentrated under reduced pressure. To the resulting residue were added water (100 ml) and saturated aqueous sodium chloride (200 ml), and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. Subsequently, the resulting residue was purified by silica gel column chromatography (eluent: n-hexane/ethyl acetate=20/1), to afford the entitled compound N-(2-fluorophenyl)-2-methylthiopropionimide methyl ester as pale yellow oil (7.84 g, 95 %). The physico-chemical values are as follows.

¹H-NMR (CDCl₃) δ: 1.16 (6H, brs), 2.38 (3H, s), 2.81 - 2.96 (1H, m), 6.74 - 6.80 (1H, m), 6.95 - 7.09 (3H, m).

(Production Example 1)

3-Biphenyl-4-yl-4-(2-fluorophenyl)-5-isopropyl-4H-1,2,4-triazole

- 5 **[0105]** N-(2-Fluorophenyl)-2-methylthiopropionimide methyl ester (7.84 g) prepared in the Reference Example 1 and biphenyl-4-carboxylic acid hydrazide (5.25 g) were dissolved in N,N-dimethylformamide (50 ml), followed by addition of p-toluenesulfonic acid • monohydrate (941 mg), and stirred at 120 °C for 59 hours. After the reaction solution was cooled to ambient temperature, the resulting solution was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent : chloroform - chloroform/methanol=100/1 to 50/1 to 20/1), to afford 3-biphenyl-4-yl-4-(2-fluorophenyl)-5-isopropyl-4H-1,2,4-triazole as pale yellow solid (5.98 g, 68%).
- 10 Apart of the product was recrystallized from ethyl acetate, to afford the entitled compound as pale yellow crystal. The physico-chemical values are as follows.
- mp: 201-204 °C. ¹H-NMR (DMSO-d₆) δ: 1.15 (3H, d, J = 6.8Hz), 1.28 (3H, d, J = 6.8Hz), 2.72 - 2.82 (1H, m), 7.36 - 7.54 (7H, m), 7.66 - 7.71 (5H, m), 7.83 (1H, ddd, J=1.4Hz, 7.8Hz, 7.8Hz).

15

(Reference Example 2)

N-(2-Bromophenyl)-6-phenylthionicotinimide ethyl ester

20 **[0106]**

- (1) 6-Phenylnicotinic acid (10.1 g) was dissolved in dimethylformamide (100 ml), followed by addition of 1-hydroxybenzotriazole (7.54 g), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (10.7 g) and 2-bromoaniline (8.72 g), and stirred at ambient temperature for 13 hours, at 60 °C for 4 hours and at 100 °C for 2 hours.
- 25 After the reaction solution was cooled to ambient temperature, the resulting solution was concentrated under reduced pressure, followed by addition of water and chloroform. The organic layer was separated, washed sequentially in water, saturated aqueous sodium hydrogen carbonate solution and water, and dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting residue was washed with a mixture solvent of n-hexane and diisopropyl ether, to afford N-(2-bromophenyl)-6-phenylthionicotinamide as white solid (11.3 g, 63%). The physico-chemical values are as follows.

30

¹H-NMR (DMSO-d₆) δ: 7.23 - 7.31 (1H, m), 7.42 - 7.63 (5H, m), 7.75 (1H, dd, J = 1.0, 7.8Hz), 8.13 - 8.23 (3H, m), 8.42 (1H, dd, J = 2.4, 8.3Hz), 9.24 (1H, dd, J = 2.0Hz), 10.32 (1H, s).

35

(2) N-(2-Bromophenyl)-6-phenylthionicotinamide (11.3 g) was dissolved in toluene (200 ml), followed by addition of the Lawesson reagent (7.12 g), and refluxed under heating for 3 hours. The resulting residue was purified by silica gel column chromatography (eluent : toluene - toluene/acetone=20/1), to afford an oily product. Subsequently, the oily product was dissolved in ethanol (70 ml), followed by addition of aqueous 0.5 mol/liter sodium hydroxide solution (130 ml) and methyl iodide (3.0 ml), and stirred at ambient temperature for 2 hours. After ethyl acetate was added to the reaction solution to separate the organic layer, the organic layer was washed with saturated aqueous sodium chloride and dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting residue was purified by silica gel column chromatography (developing solvent: n-hexane/ethyl acetate=10/1), to afford the entitled compound N-(2-bromophenyl)-6-phenylthionicotinimide methyl ester as yellow oil (8.46 g, 69%). The physico-chemical values are as follows.

40

¹H-NMR (DMSO-d₆) δ: 2.85 (3H, brs), 6.60 - 8.20 (11H, m), 8.52 (1H, brs).

45

(Production Example 2)

5-[4-(2-Bromophenyl)-4H-1,2,4-triazol-3-yl]-2-phenylpyridine

- 50 **[0107]** N-(2-Bromophenyl)-6-phenylthionicotinimide methyl ester (8.46 g) prepared in the Reference Example 2 was dissolved in N,N-dimethylformamide (20 ml), followed by addition of formyl hydrazide (2.65 g) and p-toluenesulfonic acid-monohydrate (420 mg), and stirred at 140 °C for 23 hours. After the reaction solution was cooled to ambient temperature, saturated aqueous sodium hydrogen carbonate solution was added to the resulting solution, and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting residue was purified by silica gel column chromatography (eluent: chloroform/methanol=100/1), to afford the entitled compound as yellow solid (8.34 g, quantitative). The physico-chemical values are as follows.

55

FAB-MS m/z: 377 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 7.30 - 7.69 (5H, m), 7.79 - 7.91 (3H, m), 8.00 - 8.12 (3H, m), 8.66 (1H, brd, J = 2.1Hz), 8.96 (1H, s).

(Production Example 3)

5- [5-Bromo-4-(2-bromophenyl)-4H-1,2,4-triazol-3-yl] - 2-phenylpyridine

- 5 **[0108]** 5- [4-(2-Bromophenyl)-4H-1,2,4-triazol-3-yl] -2-phenylpyridine prepared in the Production Example 2 was dissolved in a mixture solvent of carbon tetrachloride (100 ml) and acetic acid (100 ml), followed by addition of n-bromosuccinimide (5.90 g), and refluxed under heating for 3 hours. After the reaction solution was cooled to ambient temperature, the solution was concentrated under reduced pressure. Saturated aqueous sodium hydrogen carbonate solution was added to the resulting residue, and extracted with chloroform. Subsequently, the organic layer was dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting residue was purified by silica gel column chromatography (eluent : n-hexane/ethyl acetate=3/1), to afford the entitled compound as yellow solid (6.96 g, 69 %). The physico-chemical values are as follows.
 10 FAB-MS m/z: 454 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 7.43 - 7.52 (3H, m), 7.62 (1H, ddd, J = 2.0, 7.8, 7.8Hz), 7.71 (1H, ddd, J = 1.5, 7.8, 7.8Hz), 7.83 (1H, dd, J = 2.5, 8.3Hz), 7.92 - 7.98 (2H, m), 8.05 (1H, dd, J = 1.0, 8.3Hz), 8.06 - 8.11 (2H, m), 8.67 (1H, dd, J = 1.0, 2.5Hz).

(Reference Example 3)

N-(2,1,3-Benzooxadiazol-4-yl)-6-phenylthionicotinimide methyl ester

- 20 **[0109]** In the same manner as in the Reference Example 1, the entitled compound as yellow oil was obtained from 2,1,3-benzooxadiazol-4-ylamine and 6-phenylnicotinoyl chloride. The physico-chemical values are as follows.
¹H-NMR (CDCl₃) δ: 2.60 (3H, s), 6.53- 6.55 (1H, m), 7.20 - 7.96 (9H, m), 8.65 - 8.72 (1H, m).

25 (Production Example 4)

4- [3-(6-Phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2,1,3-benzooxadiazole

- 30 **[0110]** In the same manner as in the Production Example 2, the entitled compound as yellow solid was obtained (2.80 g, 96 %) from N-(2,1,3-benzooxadiazol-4-yl)-6-phenylthionicotinimide methyl ester (2.96 g) prepared in the Reference Example 3. The physico-chemical values are as follows.
 FAB-MS m/z: 341 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 7.45 - 7.53 (3H, m), 7.78 (1H, m), 7.88 (1H, d, J = 7.0Hz), 7.91 - 8.05 (4H, m), 8.26 (1H, d, J = 9.0Hz), 8.81 (1H, m), 9.15 (1H, s).

35 (Production Example 5)

4- [3-Bromo-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2,1,3-benzooxadiazole

- 40 **[0111]** In the same manner as in the Production Example 3, the entitled compound as yellow solid was obtained (1.01 g, 46 %) from 4- [3-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2,1,3-benzooxadiazole (1.80 g) recovered in the Production Example 4. The physico-chemical values are as follows.

FAB-MS m/z: 419 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 7.45 - 7.53 (3H, m), 7.85 - 7.91 (2H, m), 7.95 (1H, d, J = 8.3Hz), 8.03 - 8.08 (2H, m), 8.18 (1H, d, J = 6.9Hz), 8.41 (1H, d, J = 9.3Hz), 8.76 (1H, d, J = 1.9Hz).

[0112] In the same manner, compounds shown in Table (1) were synthetically prepared.

- 45 **[0113]** In the table, the abbreviations represent the following.

Pr.Ex. : Production Example No.

Ph : phenyl

Pyr : pyridyl

50 Me: methyl

Et : ethyl

iPr: isopropyl

cPr : cyclopropyl

cHex : cyclohexyl

55 Ac : acetyl


Bz : benzoyl

Py : pyridyl

Qin : quinolyl

Im : imidazolyl.

[0114] Herein, the substituting position of a substituent capable of substituting plural positions is expressed before the substituent (ex. 6-Br). Additionally, the binding position of hetero ring is expressed before the hetero ring (ex. 4-Py, 2-Qin).



(1)

PrEx.	Ra	Ring A	Substituent on ring A	Ring B	Substituent on ring B	Ring D	Substituent on ring D	DATA: MS m/z
6	Me	Ph	2-OMe	Ph	H	2-thiophen	H	M ⁺ +H: (ESI) 348
7	Me	Ph	2-OMe	Ph	H	2-benzofuran	H	M ⁺ +H: (ESI) 382
8	Me	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 330
9	Et	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: 344 (FAB)
10	Me	Ph	2-NH ₃	Ph	H	Ph	H	M ⁺ +H: (FAB) 327
11	Me	Ph	1H-Im-1-yl	Ph	H	Ph	H	M ⁺ +H: (FAB) 378
12	Me(CH ₂) ₂	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 358
13	Me(CH ₂) ₃	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 372
14	Me(CH ₂) ₄	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 386
15	Me(CH ₂) ₅	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 400
16	Me ₂ CHCH ₂	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 372
17	Me	Ph	2-OMe	Ph	H	Ph	H	M ⁺ +H: (FAB) 356
18	Me	Ph	5-NO ₂	Ph	H	Ph	H	M ⁺ +H: (FAB) 387
19	Me	Ph	5-CF ₃	Ph	H	Ph	H	M ⁺ +H: (FAB) 410
20	Me	Ph	4-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 330
21	Et	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 362
22	Et	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 362
23	Et	Ph	2-Cl	Ph	H	Ph	H	M ⁺ +H: (FAB) 394
24	Et	Ph	2-Cl	Ph	H	Ph	H	M ⁺ +H: (FAB) 394
25	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 340
26	Me	Ph	2-NHMe	Ph	H	Ph	H	M ⁺ +H: (FAB) 341
27	Me	Ph	2-OMe	Ph	H	Ph	3, 5-di-Cl	M ⁺ : (ESI) 410
28	Me ₂ CH-	Ph	H	Ph	H	Ph	H	M ⁺ +H: (FAB) 340
29	Me ₃ C-	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 372
30	Br-	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 395

(continued)

PrEx.	Ra	Ring A	Substituent on ring A	Ring B	Substituent on ring B	Ring D	Substituent on ring D	DATA: MS m/z
31	Me	Ph	2-Et	Ph	H	Ph	H	M ⁺ +H: (FAB) 340
32	Me	Ph	2-Me(CH ₂) ₂	Ph	H	Ph	H	M ⁺ +H: (FAB) 354
33	Et	Ph	2-OH	Ph	H	Ph	H	M ⁺ +H: (FAB) 342
34	Me	Ph	2-F	Ph	H	Ph	3,5-di-CF ₃	M ⁺ +H: (FAB) 466
35	Me	Ph	3-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 330
36	Me	Ph	3-CF ₃	Ph	H	Ph	3,5-di-CF ₃	M ⁺ +H: (FAB) 516
37	Et	Ph	3-CF ₃	Ph	H	Ph	H	M ⁺ +H: (FAB) 412
38	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 408
39	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 354
40	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 358
41	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 374
42	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 418
43	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 355
44	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 383
45	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 356
46	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 370
47	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 365
48	Et	Ph	3-C≡CH	Ph	H	Ph	H	M ⁺ +H: (FAB) 364
49	Et	Ph	2-Me	Ph	H	Ph	H	M ⁺ +H: (FAB) 385
50	Et	Ph	2-Cl	Ph	H	Ph	H	M ⁺ +H: (FAB) 385
51	Et	Ph	2-F	Ph	H	Ph	H	M ⁺ +H: (FAB) 369
52	Et	Ph	2-OH	Ph	H	Ph	H	M ⁺ +H: (FAB) 367
53	Et	Ph	2-F	Ph	2-Cl	Ph	H	M ⁺ +H: (FAB) 378
54	Et	Ph	2-F	Ph	3-Cl	Ph	H	M ⁺ +H: (FAB) 378

(Reference Example 4)

N-(2,6-Difluorophenyl)-2-methylthiopropionimide methyl ester

5 [0115] In the same manner as in the Reference Example 1, the entitled compound as colorless oil was obtained from 2,6-difluoroaniline. The physico-chemical values are as follows.
FAB-MS m/z: 230 (M⁺+H).

(Example 1)

10

5- [4-(2,6-Difluorophenyl)-5-isopropyl-4H-triazol-3-yl] - 2-phenylpyridine

[0116] In the same manner as in the Production Example 1, the entitled compound as white crystal (recrystallized from ethyl acetate) was obtained (467 mg, 35 %) from N-(2,6-difluorophenyl)-2-methylthiopropionimide methyl ester (2.32 g) prepared in the Reference Example 4 and 6-phenylnicotinic acid hydrazide (750 mg). The physico-chemical values are as follows.

mp: 183-185°C. ¹H-NMR (DMSO-d₆) δ: 1.24 (6H, d, J = 8Hz), 2.76 - 2.85 (1H, m), 7.44 - 7.56 (5H, m), 7.76 - 7.85 (2H, m), 8.05 (1H, dd, J = 8.3Hz), 8.06 - 8.12 (2H, m), 8.64 (1H, d, J = 1.9Hz).

20 (Reference Example 5)

N-(2,1,3-Benzoxadiazol-4-yl)-2-methylthiopropionimide methyl ester

[0117] In the same manner as in the Reference Example 1, the entitled compound was obtained as yellow oil from 2,1,3-benzoxadiazol-4-ylamine. The physico-chemical values are as follows.

¹H-NMR (CDCl₃) δ: 1.20 (6H, d, J = 6.8Hz), 2.91 (1H, m), 6.56 (1H, dd, J = 0.6, 6.8Hz), 7.35 (1H, dd, J = 9.2, 6.9Hz), 7.47 (1H, dd, J = 0.7, 9.0Hz).

(Example 2)

30

4- [3-Isopropyl 5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2,1,3-benzoxadiazole

[0118] In the same manner as in the Production Example 1, the entitled compound as white crystal (recrystallized from a mixture solvent of n-hexane and toluene) was obtained (126 mg, 22 %) from N-(2,1,3-benzoxadiazol-4-yl)-2-methylthiopropionimide methyl ester (323 mg) prepared in the Reference Example 5 and 6-phenylnicotinic acid hydrazide (500 mg). The physico-chemical values are as follows.

mp: 107-108 °C. ¹H-NMR (DMSO-d₆) δ: 1.12 (3H, d, J = 6.9Hz), 1.29 (3H, d, J = 6.9Hz), 2.86 - 2.98 (1H, m), 7.40 - 7.50 (3H, m), 7.78 - 7.86 (2H, m), 7.91 (1H, d, J = 8.3Hz), 8.01 - 8.05 (2H, m), 8.12 (1H, d, J = 6.8Hz), 8.34 (1H, d, J = 8.8Hz), 8.69 (1H, d, J = 2.0Hz).

40

(Example 3)

5-(3-Biphenyl-4-yl-5-ethyl-4H-1,2,4-triazol-4-yl)isoquinoline

45 [0119] A mixture of 2-biphenyl-4-yl-5-ethyl-1,3,4-oxadiazole (3.00 g), 5-aminoisoquinoline (3.00 g) and p-toluenesulfonic acid monohydrate (0.65 g) was stirred at 150 °C for 3 hours, followed by addition of p-toluenesulfonic acid monohydrate (0.65 g), and further stirred at 180 °C for 6 hours. The reaction mixture was cooled to ambient temperature, followed by addition of water and chloroform. Subsequently, potassium carbonate was added to the mixture, to adjust the mixture to basic. After the organic layer was separated, the aqueous layer was extracted with chloroform. The organic layers were combined together, washed with saturated aqueous sodium chloride, and dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting residue was purified by alumina column chromatography (eluent: chloroform) and subsequently by silica gel column chromatography (eluent: chloroform/methanol = 20/1), and was then recrystallized from ethyl acetate, to afford the entitled compound as colorless needle crystal (1.45 g, 32 %). The physico-chemical values are as follows.

55 mp: 228-230 °C. ¹H-NMR (CDCl₃) δ: 1.09 (3H, t, J = 7.6Hz), 2.33 - 2.50 (2H, m), 7.11 (1H, d, J = 5.8Hz), 7.31 - 7.42 (5H, m), 7.53 - 7.58 (4H, m), 7.89 - 7.91 (1H, t, J = 7.9Hz), 8.17 (1H, d, J = 7.4Hz), 8.42 (1H, d, J = 8.3Hz), 8.54 (1H, d, J = 6.3Hz), 9.51 (1H, s).

(Reference Example 6)

3-Amino-2-methylbenzamide

- 5 [0120] 2-Methyl-3-nitrobenzamide (8.85 g) was dissolved in a mixture solvent of ethanol (300 ml) and tetrahydrofuran (200 ml), followed by addition of 10 % palladium-carbon (800 mg). The resulting mixture was stirred under hydrogen atmosphere at ambient temperature and atmospheric pressure for 6 hours. After insoluble materials were filtered off, the filtrate was concentrated under reduced pressure and washed with isopropyl ether, to afford the entitled compound as white solid (6.73 g, 91 %). The physico-chemical values are as follows.
- 10 ¹H-NMR (DMSO-d₆) δ: 2.04 (3H, s), 4.91 (2H, s), 6.51 (1H, dd, J = 1.0 Hz, 7.5 Hz), 6.64 (1H, dd, J = 1.0 Hz, 7.5 Hz), 6.88 (1H, dd, J = 7.0 Hz, 7.5 Hz), 7.18 (1H, s), 7.51 (1H, s).

(Reference Example 7)

- 15 5-[5-(3-Methoxypropyl)-1,3,4-oxadiazol-2-yl]-2-phenylpyridine

[0121]

- (1) Carbazic acid tert-butyl ester (9.21 g) was dissolved in pyridine (120 ml), followed by addition of 4-methoxybutyric acid (9.06 g) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (20.0 g), and stirred at ambient temperature for 64 hours. After the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the residue, which was then washed with aqueous 1 mol/liter hydrochloric acid solution, saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride, and dried over anhydrous sodium sulfate. After the solvent was evaporated under reduced pressure, N'-(4-methoxybutyryl)hydrazine carboxylic acid tert-butyl ester was obtained in yellow oil (9.30 g, 57 %). The physico-chemical values are as follows.
- ¹H-NMR (DMSO-d₆) δ: 1.39 (9H, s), 1.65 - 1.78 (2H, m), 2.07 - 2.12 (2H, m), 3.21 (3H, s), 3.30 - 3.34 (2H, m), 8.64 (1H, s), 9.46 (1H, s).
- (2) N'-(4-Methoxybutyryl)hydrazine carboxylic acid tert-butyl ester (9.30 g) was dissolved in ethyl acetate (50 ml), followed by addition of 4 mol/liter hydrochloric acid/ethyl acetate solution (150 ml), and stirred at ambient temperature for 2 hours. After the reaction solution was concentrated under reduced pressure, the resulting residue was washed with n-hexane, to afford 4-methoxybutyric acid hydrazide hydrochloride salt as pale yellow solid (5.99 g, 89 %). The physico-chemical values are as follows.
- ¹H-NMR (DMSO-d₆) δ: 1.71 - 1.80 (2H, m), 2.27 (2H, t, J = 7.5 Hz), 3.22 (3H, s), 3.31 (2H, t, J = 6.3 Hz), 10.43 (3H, brs), 11.04 (1H, s).
- (3) 6-Phenylnicotinic acid (5.90 g) was dissolved in pyridine (150 ml), followed by addition of 4-methoxybutyric acid hydrazide hydrochloride salt (5.99 g) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (8.51 g), and stirred at 60 °C for 10 hours. After the reaction solution was cooled to ambient temperature, the solvent was evaporated under reduced pressure. The resulting residue was washed with water, to afford 6-phenylnicotinic acid N'-(4-methoxybutyryl)hydrazide as pale yellow solid (6.06 g, 65 %). The physico-chemical values are as follows.
- ¹H-NMR (DMSO-d₆) δ: 1.75 - 1.84 (2H, m), 2.26 (2H, t, J = 7.4 Hz), 3.25 (3H, s), 3.37 (2H, t, J = 6.4 Hz), 7.43 - 7.57 (3H, m), 8.11 - 8.19 (3H, m), 8.31 (1H, dd, J = 2.7 Hz, 8.3 Hz), 9.10 - 9.12 (1H, m), 9.96 (1H, brs), 10.53 (1H, brs).
- (4) To 6-phenylnicotinic acid N'-(4-methoxybutyryl)hydrazide (6.06 g) was added phosphorus oxychloride (100 ml), and stirred at 100 °C for 3 hours. After the reaction solution was cooled to ambient temperature, the solution was concentrated under reduced pressure. To the resulting residue was added aqueous 1 mol/liter sodium hydroxide solution under ice cooling, and extracted with chloroform. After the organic layer was dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: n-hexane/ethyl acetate = 3/1 to 1/1 to 1/2 to 1/5), and washed with a mixture solvent of n-hexane and ethyl acetate, to afford the entitled compound 5-[5-(3-methoxypropyl)-1,3,4-oxadiazol-2-yl]-2-phenylpyridine 3.72 g, 65 %). The physico-chemical values are as follows.
- ¹H-NMR (DMSO-d₆) δ: 2.01 - 2.10 (2H, m), 3.02 (2H, t, J = 7.4 Hz), 3.28 (3H, s), 3.47 (2H, t, J = 6.0 Hz), 7.46 - 7.56 (3H, m), 8.13 - 8.22 (3H, m), 8.40 (1H, dd, J = 2.2 Hz, 8.4 Hz), 9.22 - 9.23 (1H, m).

(Example 4)

3- [3-(3-Methoxypropyl)-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2-methylbenzamide

5 **[0122]** 5- [5-(3-Methoxypropyl)-1,3,4-oxadiazol-2-yl] -2-phenylpyridine (1.0 g) prepared in the Reference Example 7 was dissolved in 1,3-dimethyl-2-imidazolidinone (10 ml), followed by addition of 3-amino-2-methylbenzamide (1.53 g) prepared in the Reference Example 6 and D-10-camphorsulfonic acid (290 mg), and stirred at 200 °C for 16 hours. After the reaction solution was cooled to ambient temperature, chloroform was added to the solution, which was then washed with saturated aqueous sodium hydrogen carbonate solution. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent : chloroform/methanol = 10/1), to afford the entitled compound (812 mg, 56 %). The physico-chemical values are as follows.
FAB-MS m/z: 428 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 1.86 - 1.93 (2H, m), 1.89 (3H, s), 2.46 - 2.54 (2H, m), 3.17 (3H, s), 3.34 - 3.37 (2H, m), 7.43 - 7.53 (4H, m), 7.58 - 7.62 (2H, m), 7.67 (1H, brd, J = 7.3Hz), 7.83 (1H, dd, J = 2.4Hz, 8.3Hz), 7.96 - 8.00 (2H, m), 8.06 - 8.09 (2H, m), 8.60 (1H, d, J = 2.4Hz).

(Example 5)

3-[3-(3-Methoxypropyl)-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2-methylbenzonitrile

20 **[0123]** Phosphorus oxychloride (8 ml) was added to 3- [3-(3-methoxypropyl)-5-(6-phenylpyridin-3-yl)-1,2,4-triazol-4-yl] -2-methylbenzamide (770 mg) prepared in the Example 4, and refluxed under heating for 3 hours. After the reaction solution was cooled to ambient temperature, the solution was concentrated under reduced pressure. Chloroform was added to the resulting residue, which was then washed with saturated aqueous sodium hydrogen carbonate solution. Subsequently, the organic layer was dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting solid was recrystallized from ethyl acetate, to afford the entitled compound as white crystal (386 mg, 52 %). The physico-chemical values are as follows.
mp: 144-145 °C. ¹H-NMR (DMSO-d₆) δ: 1.84 - 1.92 (2H, m), 2.08 (3H, s), 2.45 - 2.61 (2H, m), 3.17 (3H, s), 3.35 (2H, t, J = 6.4Hz), 7.43 - 7.52 (3H, m), 7.68 (1H, t, J = 7.8Hz), 7.77 (1H, dd, J = 8.3, 1.9Hz), 7.97 - 8.02 (2H, m), 8.06 - 8.12 (3H, m), 8.64 (1H, d, J = 2.5Hz).

(Reference Example 8)

5-(5-Ethyl-1,3,4-oxadiazol-2-yl)-2-phenylpyridine

35 **[0124]** In the same manner as in the Reference Example 7, the entitled compound was obtained as pale yellow solid from propionic acid. The physico-chemical values are as follows.
¹H-NMR (DMSO-d₆) δ: 1.37 (3H, t, J = 7.6Hz), 2.99 (2H, q, J = 7.6Hz), 7.43 - 7.58 (3H, m), 8.16 - 8.21 (3H, m), 8.41 (1H, dd, J = 2.2Hz, 8.4Hz), 9.22 - 9.24 (1H, m).

(Example 6)

3- [3-Ethyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2-methylbenzonitrile

45 **[0125]** In the same manner as in Example 4, 3-[3-ethyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2-methylbenzamide as yellow solid (550 mg, 57 %) was obtained from 5-ethyl-1,3,4-oxadiazol-2-yl)-2-phenylpyridine (630 mg) prepared in the Reference Example 8 and 3-amino-2-methylbenzamide (1.13 g) prepared in the Reference Example 6.
[0126] Subsequently, the entitled compound as white crystal was obtained (242 mg, 46 %) from 3-[3-ethyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] -2-methylbenzamide (550 mg). The physico-chemical values are as follows.
mp: 162-163 °C. ¹H-NMR (DMSO-d₆) δ: 1.19 (3H, t, J = 7.5Hz), 2.08 (3H, s), 2.41 - 2.59 (2H, m), 7.43 - 7.52 (3H, m), 7.67 (1H, dd, J = 7.8, 8.3Hz), 7.76 (1H, dd, J = 2.5, 8.3Hz), 7.98 - 8.02 (2H, m), 8.05 - 8.12 (3H, m), 8.64 (1H, d, J = 2.5Hz).

(Example 7)

55 [4-(2-Bromophenyl)-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-1-yl] -N-(2-methoxyethyl)-N-methylamine

[0127] In a sealed tube, N-(2-methoxyethyl)methylamine (3 ml) was added to 5-[5-bromo-4-(2-bromophenyl)-4H-1,2,4-triazol-3-yl] -2-phenylpyridine (1.0 g) prepared in the Production Example 3, and stirred at 180 °C for 13 hours

and at 200 °C for 24 hours. After the reaction solution was cooled to ambient temperature, chloroform was added to the solution, which was then washed with saturated aqueous sodium hydrogen carbonate solution. The organic layer was dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting residue was washed with ethyl acetate, to afford the entitled compound as white solid (711 mg, 70 %). The physico-chemical values are as follows.

FAB-MS m/z: 464 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 2.77 (3H, s), 3.15 (3H, s), 3.15 - 3.31 (4H, m), 7.43 - 7.52 (4H, m), 7.65 (1H, t, J = 7.8Hz), 7.73 (1H, dd, J = 2.0, 8.3Hz), 7.85 (1H, d, J = 8.3Hz), 7.96 - 7.98 (2H, m), 8.04 - 8.07 (2H, m), 8.56 (1H, d, J = 2.4Hz).

(Example 8)

2- {3- [N-(2-Methoxyethyl)-N-methylamino] -5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl} benzonitrile

[0128] [4-(2-Bromophenyl)-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-3-yl] -N-(2-methoxyethyl)-N-methylamine (436 mg) prepared in the Example 7 was dissolved in N-methyl-2-pyrrolidone (5 ml), followed by addition of zinc cyanide (121 mg), calcium hydroxide (76 mg) and tetrakis(triphenylphosphine) palladium (326 mg), and stirred at 180 °C for 3 hours. After the reaction solution was cooled to ambient temperature, chloroform was added to the solution, from which insoluble materials were filtered off. The filtrate was washed with saturated aqueous sodium hydrogen carbonate solution, and the organic layer was dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting solid was recrystallized from ethyl acetate, to afford the entitled compound as white crystal (242 mg, 63 %). The physico-chemical values are as follows.

mp: 148-149 °C. ¹H-NMR (DMSO-d₆) δ: 2.79 (3H, s), 3.11 (2H, t, J = 5.8Hz), 3.14 (3H, s), 3.25 - 3.33 (2H, m), 7.43 - 7.52 (3H, m), 7.72 (1H, dd, J = 2.5Hz, 8.8Hz), 7.79 (1H, dt, J = 1.0Hz, 7.8Hz), 7.96 - 8.02 (2H, m), 8.04 - 8.12 (4H, m), 8.56 (1H, d, J = 2.0Hz).

(Example 9)

4-(2,1,3-Benzooxadiazol-4-yl)-N-(2-methoxyethyl)-N-methyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-3-ylamine

[0129] In a sealed tube, N-(2-methoxyethyl)methylamine (3 ml) and water (3 ml) were added to 4-[3-bromo-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzooxadiazol(336 mg) prepared in the Production Example 5, and stirred at 160 °C for 6 hours. After the reaction solution was cooled to ambient temperature, chloroform was added to the solution, which was then washed with saturated aqueous sodium hydrogen carbonate solution. The organic layer was dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting solid was recrystallized from ethyl acetate, to afford the entitled compound as white crystal (66 mg, 19 %). The physico-chemical values are as follows.

mp: 133-134 °C. ¹H-NMR (DMSO-d₆) δ: 2.76 (3H, s), 3.00 (3H, s), 3.05 - 3.25 (4H, m), 7.40 - 7.50 (3H, m), 7.75 - 7.82 (2H, m), 7.90 (1H, d, J = 8.8Hz), 8.00 - 8.10 (3H, m), 8.30 (1H, d, J = 9.3Hz), 8.67 (1H, d, J = 2.5Hz).

(Reference Example 9)

N-(2-Fluorophenyl)thioacetimidate methyl ester

[0130] In the same manner as in the Reference Example 1, the entitled compound was obtained in pale yellow oil from 2-fluoroaniline. The physico-chemical values are as follows.

¹H-NMR (CDCl₃) δ: 1.59 (3H, brs), 2.02 (3H, brs), 6.78 - 6.85 (1H, m), 6.98 - 7.11 (3H, m).

(Reference Example 10)

3-(4-Bromophenyl)-4-(2-fluorophenyl)-5-methyl-4H-1,2,4-triazole

[0131] In the same manner as in the Production Example 1, the entitled compound was obtained as white solid (810 mg, 89 %) from N-(2-fluorophenyl)thioacetimidate methyl ester (500 mg) prepared in the Reference Example 9 and 4-bromobenzic acid hydrazide (705 mg). The physico-chemical values are as follows.

FAB-MS m/z: 332 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 2.25 (3H, s), 7.28 - 7.75 (8H, m).

(Example 10)

4-(2-Fluorophenyl)-3-methyl-5-(4-thiophen-2-ylphenyl)-4H-1,2,4-triazole

5 **[0132]** 3-(4-Bromophenyl)-4-(2-fluorophenyl)-5-methyl-4H-1,2,4-triazole (150 mg) prepared in the Reference Example 10 was dissolved in 1,2-dimethoxyethane (2 ml), followed by addition of tetrakis(triphenylphosphine) palladium (26 mg), and stirred at ambient temperature for 15 minutes. Subsequently, a solution of 2-thiophenboric acid (150 mg) in ethanol (0.5 ml) and aqueous 2 mol/liter sodium carbonate solution (0.45 ml) were added to the resulting mixture, and refluxed under heating for 4 hours. After the reaction solution was cooled to ambient temperature, insoluble materials were filtered off. To the resulting filtrate was added saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel chromatography (eluent: chloroform/methanol=99/1 to 97/3) and recrystallized from ethanol, to afford the entitled compound as white solid (100 mg, 66 %). The physico-chemical values are as follows.

15 FAB-MS m/z: 336 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 2.24 (3H, s), 7.12 (1H, dd, J = 3.5, 4.5 Hz), 7.38 - 7.68 (10H, m).

(Example 11)

3-[4-[4-(2-Fluorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]phenyl]pyridine

20 **[0133]** 3-(4-Bromophenyl)-4-(2-fluorophenyl)-5-methyl-4H-1,2,4-triazole (500 mg) prepared in the Reference Example 10 was dissolved in tetrahydrofuran (15 ml), followed by addition of n-butyl lithium (1.57 mol/liter hexane solution; 1.2 ml) at -78 °C, and stirred at the same temperature for 20 minutes. Borate methyl ester (0.50 ml) was added to the mixture and stirred at ambient temperature for 3 hours. Under ice cooling, aqueous 2 mol/liter hydrochloric acid solution was added to adjust the solution to about pH 4, followed by extraction with chloroform. The organic layer was washed with saturated aqueous saline. The organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure, to afford a borate derivative as pale yellow oil (660 mg).

25 **[0134]** 3-Bromopyridine (0.15 ml) was dissolved in 1,2-dimethoxyethane (5 ml), followed by addition of tetrakis(triphenylphosphine) palladium (87 mg), and stirred at ambient temperature for 15 minutes. To the reaction solution were added a solution of the borate derivative in ethanol (2 ml) and aqueous 2 mol/liter sodium carbonate solution (1.5 ml), and refluxed heating for 3 hours. After the reaction solution was cooled to ambient temperature, insoluble materials were filtered off, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel chromatography (eluent: chloroform/methanol 98/2) and washed with a mixture solvent of n-hexane and ethyl acetate, to afford the entitled compound as white solid (140 mg, 28 %). The physico-chemical values are as follows.

30 FAB-MS m/z: 331 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 2.26 (3H, s), 7.44 - 7.56 (5H, m), 7.63 - 7.70 (1H, m), 7.74 - 7.79 (3H, m), 8.07 - 8.11 (1H, m), 8.56 - 8.60 (1H, m), 8.88 - 8.92 (1H, m).

(Example 12)

40 3-Biphenyl-4-yl-4-(2-fluorophenyl)-5-methylsulfanyl-4H-1,2,4-triazole

[0135]

45 (1) Biphenyl-4-carboxylic acidhydrazide (10.0 g) was dissolved in ethanol (250 ml), followed by addition of 2-fluorophenylisothiocyanate (5.8 ml), and stirred at ambient temperature for 2 hours. The precipitate was filtered, to afford 1-(biphenyl-4-carbonyl)-4-(2-fluorophenyl)-thiosemicarbazide as white solid (12.3 g, 72 %). The physico-chemical values are as follows.

FAB-MS m/z: 366 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 7.15 - 7.45 (5H, m), 7.50 (2H, t, J = 7.5 Hz), 7.75 (2H, d, J = 7.5 Hz), 7.82 (2H, d, J = 8.5 Hz), 8.05 (2H, d, J = 8.5 Hz), 9.64 (1H, s), 9.89 (1H, s), 10.66 (1H, s).

50 (2) 1-(Biphenyl-4-carbonyl)-4-(2-fluorophenyl)thiosemicarbazide (12.1 g) was suspended in aqueous 2 mol/liter sodium hydroxide solution (300 ml), and refluxed under heating for 3 hours. After the reaction solution was cooled to ambient temperature, the solution was neutralized under ice cooling with conc. hydrochloric acid. The precipitate was filtered and washed with water, to afford 5-biphenyl-4-yl-4-(2-fluorophenyl)-4H-1,2,4-triazole-3-thiol as pale yellow solid (11.2 g, 97 %). The physico-chemical values are as follows.

55 FAB-MS m/z: 348 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 7.33 - 7.52 (8H, m), 7.53 - 7.70 (6H, m).

(3) 5-Biphenyl-4-yl-4-(2-fluorophenyl)-4H-1,2,4-triazole-3-thiol (2.7 g) was dissolved in acetonitrile (50 ml), followed by addition of methyl iodide (0.967 ml) and potassium carbonate (1.07 g), and stirred at ambient temperature for 3 hours. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer

was washed with saturated aqueous saline and dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting solid was recrystallized from a mixture solvent of acetonitrile and ethyl acetate to afford the entitled compound 3-biphenyl-4-yl-4-(2-fluorophenyl)-5-methylsulfanyl-4H-1,2,4-triazole as pale yellow crystal (2.03 g, 72%). The physico-chemical values are as follows.

mp: 199-200 °C. ¹H-NMR (DMSO-d₆) δ: 2.65 (3H, s), 7.35 - 7.56 (7H, m), 7.65 - 7.72 (5H, m), 7.77 (1H, dt, J = 2.0, 7.8 Hz).

(Example 13)

3-Benzyloxymethyl-5-biphenyl-4-yl-4-(2-fluorophenyl)-4H-1,2,4-triazole

[0136]

(1) Biphenyl-4-carboxylic acid hydrazide (6.4 g) was dissolved in N,N-dimethylformamide (50 ml), followed by sequential addition of tetrahydrofuran (100 ml), benzyloxyacetic acid (5.0 g), 1-hydroxybenzotriazole (0.30 g) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt (6.3 g), and stirred at ambient temperature for 2 hours. After the reaction solution was concentrated under reduced pressure, water was added to the resulting residue, and the precipitate was filtered. The precipitate was sequentially washed with aqueous 0.15 mol/liter hydrochloric acid solution and water, to afford biphenyl-4-carboxylic acid N'-(2-benzyloxyacetyl)hydrazide as pale yellow solid (10.8 g, quantitative). The physico-chemical values are as follows.

FAB-MS m/z: 361.

(2) To biphenyl-4-carboxylic acid N'-(2-benzyloxyacetyl)hydrazide (9.38 g) was added phosphorus oxychloride (30 ml), and stirred at 100 °C for one hour. After the reaction solution was cooled to ambient temperature, the reaction solution was concentrated under reduced pressure. To the resulting residue was added ethyl acetate, and the separated organic layer was washed with aqueous 1 mol/liter sodium hydroxide solution and dried over anhydrous magnesium sulfate, and the solvent was evaporated under reduced pressure to afford an oily product. Subsequently, 2-fluoroaniline (5 ml) and p-toluenesulfonic acid monohydrate (200 mg) were added to the resulting oily product, and stirred at 140 °C for 4 hours. After the reaction solution was cooled to ambient temperature, ethyl acetate was added to the reaction solution. The separated organic layer was washed with aqueous 1 mol/liter sodium hydroxide solution and dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel chromatography (eluent: n-hexane/ethyl acetate = 3/1 - 1/1), to afford the entitled compound 3-benzyloxymethyl-5-biphenyl-4-yl-4-(2-fluorophenyl)-4H-1,2,4-triazole as pale yellow solid (6.60 g, 58%). The physico-chemical values are as follows.

FAB-MS m/z: 436 (M⁺+H). ¹H-NMR (DMSO-d₆) δ: 4.35 (1H, d, J = 11.9 Hz), 4.40 (1H, d, J = 11.9 Hz), 7.06 - 7.12 (2H, m), 7.23 - 7.52 (10H, m), 7.62 - 7.73 (5H, m), 7.81 (1H, ddd, J = 1.7, 8.0, 9.5 Hz).

(Example 14)

[5-Biphenyl-4-yl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl] methanol

[0137] 3-Benzyloxymethyl-5-biphenyl-4-yl-4-(2-fluorophenyl)-4H-1,2,4-triazole (6.00 g) was dissolved in chloroform (200 ml), followed by dropwise addition of 1 mol/liter boron trichloride-hexane solution (30 ml) at -44 °C and stirred at the same temperature for 30 minutes and at ambient temperature for one hour. To the reaction solution were added methanol (5 ml) and saturated aqueous sodium hydrogen carbonate solution (50 ml), followed by concentration under reduced pressure. To the resulting residue were added tetrahydrofuran (100 ml), aqueous 2 mol/liter sodium hydroxide solution (100 ml) and tetrabutylammoniumhydrogensulfate (0.10 g), and stirred at ambient temperature for 12 hours. The reaction solution was extracted with ethyl acetate, and the organic layer was dried over anhydrous magnesium sulfate. After the solvent was evaporated under reduced pressure, the resulting residue was purified by silica gel chromatography (eluent: chloroform/methanol = 96/4) and recrystallized from a mixture solution of n-hexane-ethyl acetate-ethanol, to afford the entitled compound as white crystal (2.09 g, 44%). The physico-chemical values are as follows. mp: 220-223 °C. ¹H-NMR (DMSO-d₆) δ: 4.47 (1H, dd, J = 5.5, 13.2 Hz), 4.53 (1H, dd, J = 5.5, 13.2 Hz), 5.46 (1H, t, J = 5.5 Hz), 7.34 - 7.50 (7H, m), 7.59 - 7.75 (5H, m), 7.79 (1H, ddd, J = 1.5, 8.2, 9.7 Hz).

(Example 15)

3-Biphenyl-4-yl-5-chloromethyl-4-(2-fluorophenyl)-4H-1,2,4-triazole

[0138] [5-Biphenyl-4-yl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl] methanol (1.81 g) was suspended in toluene (25

ml), followed by addition of thionyl chloride (1.5 ml) and chloroform (25 ml), and stirred at 60°C for 5 hours. After the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the reaction solution, which was washed with saturated aqueous sodium hydrogen carbonate solution. After the organic layer was dried over anhydrous magnesium sulfate, the solvent was evaporated under reduced pressure. The resulting white solid was washed with a mixture solution of n-hexane and ethyl acetate, to afford the entitled compound as white solid (1.54 g, 81 %). The physico-chemical values are as follows.

FAB-MS m/z : 364 ($M^+ + H$). 1H -NMR ($DMSO-d_6$) δ : 4.80 (1H, d, $J = 13.0$ Hz), 4.87 (1H, d, $J = 13.0$ Hz), 7.34 - 7.54 (7H, m), 7.66 - 7.75 (5H, m), 7.91 (1H, ddd, $J = 1.6, 6.2, 9.2$ Hz).

(Example 16)


4- { [5-Biphenyl-4-yl-4-(2-fluorophenyl)-4H-1,2,4-triazol-3-yl] methyl} morpholine

[0139] Morpholine (0.599 ml) was dissolved in N,N-dimethylformamide (6 ml), followed by addition of sodium hydride (60 %, 275 mg) under ice cooling, and stirred at the same temperature for 30 minutes. Under ice cooling, 3-biphenyl-4-yl-5-chloromethyl-4-(2-fluorophenyl)-4H-1,2,4-triazole (599 mg) was added to the reaction solution, and stirred at ambient temperature for 17 hours. After the reaction solution was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution was added to the resulting residue, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure, and the resulting residue was purified by silica gel chromatography (eluent : toluene/acetone = 3/2 to 1/1), and recrystallized from a mixture solution of n-hexane and ethyl acetate, to afford the entitled compound as white crystal (211 mg, 74 %). The physico-chemical values are as follows.










mp: 129-131 °C. 1H -NMR ($DMSO-d_6$) δ : 2.13 - 2.26 (4H, m), 3.29 - 3.34 (4H, m), 3.50 (1H, d, $J = 14.2$ Hz), 3.63 (1H, d, $J = 14.2$ Hz), 7.36 - 7.51 (7H, m), 7.60 - 7.70 (5H, m), 7.81 - 7.85 (1H, m).


















[0140] The following Tables (2) and (3) show the structural formulas and physico-chemical properties of the compounds of the Example.


















[0141] In the tables, the abbreviation 'Ex' represents Example. Other abbreviations are as described above.






























































(2)






































Ex.		A'	Ra	DATA: MS m/z
17	biphenyl-4-yl		Me	M ⁺ +H: 362 (FAB)
18	biphenyl-4-yl	indan-2-yl	Et	M ⁺ +H: 366 (FAB)
19	biphenyl-4-yl	cHex	Et	M ⁺ +H: 332 (FAB)
20	biphenyl-4-yl	morpholin-4-yl	Me	M ⁺ +H: 321 (FAB)
21	biphenyl-4-yl	1H-pyrazol-3-yl	Me	M ⁺ +H: 302 (FAB)
22	biphenyl-4-yl	2-Ph-2H-pyrazol-3-yl	Et	M ⁺ +H: 392 (FAB)
23	biphenyl-4-yl	3-Me-pyridin-2-yl	Me	M ⁺ +H: 327 (FAB)
24	biphenyl-4-yl	pyridin-3-yl	Me	M ⁺ +H: 313 (FAB)
25	biphenyl-4-yl	2-Cl-pyridin-3-yl	Me	M ⁺ +H: 347 (FAB)
26	biphenyl-4-yl	6-Cl-pyridin-3-yl	Me	M ⁺ +H: 347 (FAB)
27	biphenyl-4-yl		Me	M ⁺ +H: 354 (FAB)
28	biphenyl-4-yl	quinolin-8-yl	Et	M ⁺ +H: 377 (FAB)
29		2-F-Ph	Me	M ⁺ +H: 321 (FAB)
30		2-F-Ph	Me	M ⁺ +H: 336 (FAB)
31		2-F-Ph	Me	M ⁺ +H: 351 (FAB)
32		2-F-Ph	Me	M ⁺ +H: 351 (FAB)
33		2-F-Ph	Me	M ⁺ +H: 331 (FAB)
34		2-F-Ph	Me	M ⁺ +H: 331 (FAB)

















Ex		A'	Ra	DATA: MS m/z
35	biphenyl-4-yl		Et	M ⁺ +H: 368 (FAB)
36	biphenyl-4-yl		Me ₂ CH-	M ⁺ +H: 382 (FAB)
37	biphenyl-4-yl		Et	M ⁺ +H: 384 (FAB)
38	biphenyl-4-yl		Et	M ⁺ +H: 366 (FAB)
39	biphenyl-4-yl		Et	M ⁺ +H: 380 (FAB)
40	biphenyl-4-yl		Et	M ⁺ +H: 376 (FAB)
41	biphenyl-4-yl		Et	M ⁺ +H: 376 (FAB)
42	biphenyl-4-yl		Et	M ⁺ +H: 365 (FAB)
43	biphenyl-4-yl		Et	M ⁺ +H: 379 (FAB)
44	biphenyl-4-yl		Et	M ⁺ +H: 366 (FAB)
45	biphenyl-4-yl		Et	M ⁺ +H: 366 (FAB)
46	biphenyl-4-yl		Et	M ⁺ +H: 366 (FAB)
47	biphenyl-4-yl		Et	M ⁺ +H: 366 (FAB)
48	biphenyl-4-yl		Et	M ⁺ +H: 366 (FAB)
49	biphenyl-4-yl		Et	M ⁺ +H: 381 (FAB)
50	biphenyl-4-yl		Et	M ⁺ +H: 391 (FAB)


Ex		A'	Ra	DATA: MS m/z
51	biphenyl-4-yl		Et	M ⁺ +H: 391 (FAB)
52	biphenyl-4-yl		Et	M ⁺ +H: 377 (FAB)
53	biphenyl-4-yl		Et	M ⁺ +H: 377 (FAB)
54	biphenyl-4-yl		Me(CH ₂) ₂ -	M ⁺ +H: 391 (FAB)
55	biphenyl-4-yl		MeO(CH ₂) ₃ -	M ⁺ +H: 421 (FAB)
56	biphenyl-4-yl		Et	M ⁺ +H: 393 (FAB)
57	biphenyl-4-yl		Et	M ⁺ +H: 411 (FAB)
58	biphenyl-4-yl		Et	M ⁺ +H: 411 (FAB)
59	biphenyl-4-yl		Et	M ⁺ +H: 411 (FAB)
60	biphenyl-4-yl		Et	M ⁺ +H: 393 (FAB)
61	biphenyl-4-yl		Et	M ⁺ +H: 381 (FAB)
62	biphenyl-4-yl		Et	M ⁺ +H: 395 (FAB)
63	biphenyl-4-yl		Me ₂ CH-	M ⁺ +H: 391 (FAB)
64	biphenyl-4-yl		Et	M ⁺ +H: 377 (FAB)
65	biphenyl-4-yl		Et	M ⁺ +H: 377 (FAB)
66	biphenyl-4-yl		Et	M ⁺ +H: 377 (FAB)

Ex		A'	Ra	DATA: MS m/z
67	biphenyl-4-yl		Et	M ⁺ +H: 377 (FAB)
68		2-F-Ph	Et	M ⁺ +H: 351 (FAB)
69		2-F-Ph	Et	M ⁺ +H: 349 (FAB)
70		2-F-Ph	Et	M ⁺ +H: 351 (FAB)
71		2-F-Ph	Et	M ⁺ +H: 352 (FAB)
72		2-F-Ph	Et	M ⁺ +H: 345 (FAB)
73		2-F-Ph	Et	M ⁺ +H: 345 (FAB)
74		2-F-Ph	Me ₂ CH-	M ⁺ +H: 359 (FAB)
75		2-F-Ph	MeO(CH ₂) ₃ -	M ⁺ +H: 389 (FAB)
76		2-F-Ph	Me ₂ N-	M ⁺ +H: 360 (FAB)
77		2-F-Ph	EtNH-	M ⁺ +H: 360 (FAB)
78		2-F-Ph		M ⁺ +H: 390 (FAB)
79		2-F-Ph		M ⁺ +H: 404 (FAB)
80		2-F-Ph		M ⁺ +H: 418 (FAB)
81		2-F-Ph		M ⁺ +H: 432 (FAB)
82		2-F-Ph		M ⁺ +H: 416 (FAB)
83		2-F-Ph		M ⁺ +H: 416 (FAB)
84		2-F-Ph		M ⁺ +H: 416 (FAB)
85		2-F-Ph	Et	M ⁺ +H: 361 (FAB)
86		2-F-Ph	Et	M ⁺ +H: 379 (FAB)

Ex		A'	Ra	DATA: MS m/z
87		2-F-Ph	Et	M ⁺ +H: 379 (FAB)
88		2-F-Ph	Et	M ⁺ +H: 388 (FAB)
89		2-F-Ph	Et	M ⁺ +H: 421 (FAB)
90		2-CN-Ph	Et	M ⁺ +H: 352 (FAB)
91		2-CN-Ph	Me ₂ CH-	M ⁺ +H: 366 (FAB)
92		2-CN-Ph	MeO(CH ₂) ₃ -	M ⁺ +H: 396 (FAB)
93		2-CN-Ph	Me ₂ N-	M ⁺ +H: 367 (FAB)
94		2-CN-Ph		M ⁺ +H: 437 (FAB)
95			Et	M ⁺ +H: 386 (FAB)
96			Me ₂ CH-	M ⁺ +H: 400 (FAB)
97			MeO(CH ₂) ₃ -	M ⁺ +H: 430 (FAB)
98			Me ₂ CH-	M ⁺ +H: 380 (FAB)
99			EtNH-	M ⁺ +H: 381 (FAB)
100				M ⁺ +H: 411 (FAB)
101				M ⁺ +H: 425 (FAB)
102				M ⁺ +H: 437 (FAB)
103			Me ₂ CH-	M ⁺ +H: 369 (ESI)

Ex		A'	Ra	DATA: MS m/z
104			Me ₂ CH-	M ⁺ +H: 409 (ESI)
105			MeO(CH ₂) ₃ -	M ⁺ +H: 407 (FAB)
106				M ⁺ +H: 419 (FAB)
107				M ⁺ +H: 433 (FAB)
108			H ₂ N-	M ⁺ +H: 350 (FAB)
109			CF ₃ CH ₂ -	M ⁺ +H: 417 (FAB)
110			CF ₃ CF ₂ -	M ⁺ +H: 453 (FAB)
111			CF ₃ (CH ₂) ₂ -	M ⁺ +H: 431 (FAB)
112			Me ₂ CH-	M ⁺ +H: 411 (FAB)
113			Me ₂ CH-	M ⁺ : 394 (FAB)
114			Me ₂ CH-	M ⁺ +H: 395 (FAB)
115			Me ₂ CH-	M ⁺ +H: 395 (FAB)
116			MeO(CH ₂) ₃ -	M ⁺ +H: 413 (FAB)
117			Me ₂ N-	M ⁺ +H: 384 (FAB)
118			Et	M ⁺ +H: 378 (FAB)
119			Me(CH ₂) ₂ -	M ⁺ +H: 392 (FAB)
120			Me ₂ CH-	M ⁺ +H: 392 (FAB)













Ex		A'	Ra	DATA: MS m/z
121			MeO(CH ₂) ₃ -	M ⁺ +H: 422 (FAB)
122			MeNH-	M ⁺ +H: 379 (FAB)
123			EtNH-	M ⁺ +H: 393 (FAB)
124			Me ₂ N-	M ⁺ +H: 393 (FAB)
125			MeOCH ₂ CH ₂ NH-	M ⁺ +H: 423 (FAB)
126			MeOCH ₂ CH ₂ NMe-	M ⁺ +H: 437 (FAB)
127				M ⁺ +H: 449 (FAB)





































(3)


Ex	Ra	Rb	(Rc) p	Rd'	Re'	DATA: MS m/z
128	MeOCH ₂ -	2-F	-	H	H	M ⁺ +H: 360 (FAB)
129	HO ₂ CCH ₂ N(Me)CH ₂ -	2-F	-	H	H	M ⁺ +H: 417 (FAB)
130	MeO ₂ CCH ₂ N(Me)CH ₂ -	2-F	-	H	H	M ⁺ +H: 431 (FAB)
131	furan-2-yl	2-F	-	H	H	M ⁺ +H: 382 (FAB)
132	MeS-	2-OMe	-	H	H	M ⁺ +H: 374 (FAB)
133	EtS-	2-OMe	-	H	H	M ⁺ +H: 388 (FAB)
134	Me(CH ₂) ₂ S-	2-F	-	H	H	M ⁺ +H: 390 (FAB)
135	Me(CH ₂) ₄ S-	2-F	-	H	H	M ⁺ +H: 418 (FAB)
136	Me(CH ₂) ₆ S-	2-F	-	H	H	M ⁺ +H: 446 (FAB)
137	CH ₂ =CHCH ₂ S-	2-F	-	H	H	M ⁺ +H: 388 (FAB)
138	CH≡CCH ₂ S-	2-F	-	H	H	M ⁺ +H: 386 (FAB)
139	cHex-CH ₂ -S-	2-F	-	H	H	M ⁺ +H: 444 (FAB)
140	cPr-CH ₂ -S-	2-F	-	H	H	M ⁺ +H: 402 (FAB)
141	NCCH ₂ S-	2-F	-	H	H	M ⁺ +H: 387 (FAB)
142	PhCH ₂ S-	2-F	-	H	H	M ⁺ +H: 438 (FAB)
143	(2,6-di-Cl-Ph)CH ₂ S-	2-F	-	H	H	M ⁺ +H: 506 (FAB)
144	(2-OMe-5-NO ₂ -Ph)CH ₂ S-	2-F	-	H	H	M ⁺ +H: 513 (FAB)
145	(4-CO ₂ Me-Ph)CH ₂ S-	2-F	-	H	H	M ⁺ +H: 496 (FAB)
146	2-Py-CH ₂ -S-	2-F	-	H	H	M ⁺ +H: 439 (FAB)
147	3-Py-CH ₂ -S-	2-F	-	H	H	M ⁺ +H: 439 (FAB)
148	4-Py-CH ₂ -S-	2-F	-	H	H	M ⁺ +H: 439 (FAB)
149	Ph(CH ₂) ₃ S-	2-F	-	H	H	M ⁺ +H: 452 (FAB)
150	H ₂ NC(O)CH ₂ S-	2-F	-	H	H	M ⁺ +H: 405 (FAB)
151	Et ₂ N(CH ₂) ₂ S-	2-F	-	H	H	M ⁺ +H: 447 (FAB)
152	Me ₂ CHS-	2-F	-	H	H	M ⁺ +H: 390 (FAB)
153	MeC(O)CH ₂ S-	2-F	-	H	H	M ⁺ +H: 404 (FAB)
154	HO ₂ CCH ₂ S-	2-F	-	H	H	M ⁺ +H: 406 (FAB)
155	Et ₂ NC(O)CH ₂ S-	2-F	-	H	H	M ⁺ +H: 461 (FAB)
156	2-Qln-CH ₂ -S-	2-F	-	H	H	M ⁺ +H: 489 (FAB)
157	HO ₂ CCH ₂ N(Me)(CH ₂) ₃ S-	2-F	-	H	H	M ⁺ +H: 477 (FAB)

Ex.	Ra	Rb	(Rc)p	Rd'	Re'	DATA: MS m/z
158	Me	2-HO ₂ CCH ₂ N(Me)(CH ₂) ₃ O-	—	H	H	M ⁺ +H: 457 (FAB)
159	Me	2-CF ₃	—	H	H	M ⁺ +H: 380 (FAB)
160	Me	2-OCF ₃	—	H	H	M ⁺ +H: 395 (FAB)
161	Me	2-CO ₂ H	—	H	H	M ⁺ +H: 356 (FAB)
162	Me	2-CONH ₂	—	H	H	M ⁺ +H: 355 (FAB)
163	Me	2-CONMe ₂	—	H	H	M ⁺ +H: 383 (FAB)
164	Me	2-pyrrol-1-yl	—	H	H	M ⁺ +H: 377 (FAB)
165	Me	2-imidazol-1-yl	—	H	H	M ⁺ +H: 378 (FAB)
166	Me	2-(1H-tetrazol-5-yl)	—	H	H	M ⁺ +H: 380 (FAB)
167	Me	2-S(O)Me	—	H	H	M ⁺ +H: 374 (FAB)
168	Me	2-SO ₂ Me	—	H	H	M ⁺ +H: 390 (FAB)
169	Me	2-SO ₂ Ph	—	H	H	M ⁺ +H: 452 (FAB)
170	Me	2-OMe	—	H	3-F	M ⁺ +H: 360 (ESI)
171	Me	2-OMe	—	H	4-F	M ⁺ +H: 360 (ESI)
172	Me	2-OMe	—	H	2-Cl	M ⁺ +H: 376 (ESI)
173	Me	2-OMe	—	H	3-Cl	M ⁺ +H: 376 (ESI)
174	Me	2-OMe	—	H	4-Cl	M ⁺ +H: 376 (ESI)
175	Me	2-OMe	—	H	2-OMe	M ⁺ +H: 372 (ESI)
176	Me	2-OMe	—	H	3-OMe	M ⁺ +H: 372 (ESI)
177	Me	2-OMe	—	H	3-OEt	M ⁺ +H: 386 (ESI)
178	Me	2-OMe	—	H	4-OMe	M ⁺ +H: 372 (ESI)
179	Me	2-OMe	—	H	4-CF ₃	M ⁺ +H: 410 (ESI)
180	Me	2-OMe	—	H	4-OCF ₃	M ⁺ +H: 426 (ESI)
181	Me	2-OMe	—	H	3-NHAc	M ⁺ +H: 399 (ESI)

Ex.	Ra	Rb	(Rc)p	Rd'	Re'	DATA: MS m/z
182	$\text{MeO}(\text{CH}_2)_2-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 374 (FAB)
183	$\text{MeO}(\text{CH}_2)_3-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 388 (FAB)
184	$\text{HO}(\text{CH}_2)_2-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 360 (FAB)
185	$\text{HO}(\text{CH}_2)_3-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 374 (FAB)
186	$\text{HO}_2\text{CCH}_2\text{N}(\text{Me})(\text{CH}_2)_2-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 431 (FAB)
187	$\text{HO}_2\text{CCH}_2\text{N}(\text{Me})(\text{CH}_2)_3-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 445 (FAB)
188		2-F	—	H	H	$\text{M}^+ + \text{H}$: 402 (FAB)
189		2-F	—	H	H	$\text{M}^+ + \text{H}$: 388 (FAB)
190	NCCH_2-	2-F	—	H	H	$\text{M}^+ + \text{H}$: 355 (FAB)
191	$\text{NC}(\text{CH}_2)_2-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 369 (FAB)
192		2-F	—	H	H	$\text{M}^+ + \text{H}$: 367 (FAB)
193	Ph-NH-CH_2-	2-F	—	H	H	$\text{M}^+ + \text{H}$: 421 (FAB)
194	$\text{Ph-N}(\text{Me})-\text{CH}_2-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 435 (FAB)
195	3-Py-O-CH ₂ -	2-F	—	H	H	$\text{M}^+ + \text{H}$: 423 (FAB)
196	imida- zol-1-yl-CH ₂ -	2-F	—	H	H	$\text{M}^+ + \text{H}$: 396 (FAB)
197	Et_3NCH_2-	2-F	—	H	H	$\text{M}^+ + \text{H}$: 401 (FAB)
198		2-F	—	H	H	$\text{M}^+ + \text{H}$: 413 (FAB)
199		2-F	—	H	H	$\text{M}^+ + \text{H}$: 415 (FAB)
200		2-F	—	H	H	$\text{M}^+ + \text{H}$: 461 (FAB)
201		2-F	—	H	H	$\text{M}^+ + \text{H}$: 461 (FAB)
202		2-F	—	H	H	$\text{M}^+ + \text{H}$: 467 (FAB)
203		2-F	—	H	H	$\text{M}^+ + \text{H}$: 414 (FAB)
204		2-F	—	H	H	$\text{M}^+ + \text{H}$: 386 (FAB)
205		2-F	—	H	H	$\text{M}^+ + \text{H}$: 489 (FAB)
206		2-F	—	H	H	$\text{M}^+ + \text{H}$: 399 (FAB)
207	$\text{H}_2\text{N}-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 331 (FAB)
208	$\text{MeNH}-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 345 (FAB)
209	$\text{EtNH}-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 359 (FAB)
210	$\text{Me}(\text{CH}_2)_2\text{NH}-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 373 (FAB)
211	$\text{Me}(\text{CH}_2)_3\text{NH}-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 387 (FAB)
212	$\text{Me}_2\text{CHNH}-$	2-F	—	H	H	$\text{M}^+ + \text{H}$: 373 (FAB)

Ex.	Ra	Rb	(Rc)p	Rd'	Re'	DATA: MS m/z
213		2-F	—	H	H	M ⁺ +H: 387 (FAB)
214		2-F	—	H	H	M ⁺ +H: 385 (FAB)
215		2-F	—	H	H	M ⁺ +H: 399 (FAB)
216		2-F	—	H	H	M ⁺ +H: 413 (FAB)
217		2-F	—	H	H	M ⁺ +H: 402 (FAB)
218		2-F	—	H	H	M ⁺ +H: 405 (FAB)
219		2-F	—	H	H	M ⁺ +H: 375 (FAB)
220		2-F	—	H	H	M ⁺ +H: 389 (FAB)
221		2-F	—	H	H	M ⁺ +H: 403 (FAB)
222		2-F	—	H	H	M ⁺ +H: 417 (FAB)
223		2-F	—	H	H	M ⁺ +H: 403 (FAB)
224		2-F	—	H	H	M ⁺ +H: 417 (FAB)
225		2-F	—	H	H	M ⁺ +H: 431 (FAB)
226		2-F	—	H	H	M ⁺ +H: 403 (FAB)
227		2-F	—	H	H	M ⁺ +H: 417 (FAB)
228		2-F	—	H	H	M ⁺ +H: 431 (FAB)
229		2-F	—	H	H	M ⁺ +H: 403 (FAB)
230		2-F	—	H	H	M ⁺ +H: 417 (FAB)
231		2-F	—	H	H	M ⁺ +H: 403 (FAB)
232		2-F	—	H	H	M ⁺ +H: 401 (FAB)
233		2-F	—	H	H	M ⁺ +H: 415 (FAB)
234		2-F	—	H	H	M ⁺ +H: 415 (FAB)

Ex.	Ra	Rb	(Rc)p	Rd'	Re'	DATA: MS m/z
235		2-F	—	H	H	M ⁺ +H: 415 (FAB)
236		2-F	—	H	H	M ⁺ +H: 429 (FAB)
237		2-F	—	H	H	M ⁺ +H: 415 (FAB)
238		2-F	—	H	H	M ⁺ +H: 443 (FAB)
239		2-F	—	H	H	M ⁺ +H: 422 (FAB)
240		2-F	—	H	H	M ⁺ +H: 422 (FAB)
241	Me ₂ N-	2-F	—	H	H	M ⁺ +H: 359 (FAB)
242	Et ₂ N-	2-F	—	H	H	M ⁺ +H: 387 (FAB)
243		2-F	—	H	H	M ⁺ +H: 373 (FAB)
244		2-F	—	H	H	M ⁺ +H: 401 (FAB)
245		2-F	—	H	H	M ⁺ +H: 382 (FAB)
246		2-F	—	H	H	M ⁺ +H: 396 (FAB)
247	CH ₃ CONH-	2-F	—	H	H	M ⁺ +H: 373 (FAB)
248	CH ₃ SO ₂ NH-	2-F	—	H	H	M ⁺ +H: 409 (FAB)
249	MeO-	2-F	—	H	H	M ⁺ +H: 346 (FAB)
250	EtO-	2-F	—	H	H	M ⁺ +H: 360 (FAB)
251	MeS-	2-F	—	H	H	M ⁺ +H: 362 (FAB)
252	EtS-	2-F	—	H	H	M ⁺ +H: 376 (FAB)
253	MeSO ₂ -	2-F	—	H	H	M ⁺ +H: 394 (FAB)
254	Me	3-CF ₃	—	H	H	M ⁺ +H: 380 (FAB)
255	Et	3-CF ₃	—	H	H	M ⁺ +H: 394 (FAB)
256	Me	2-NO ₂	—	H	H	M ⁺ +H: 357 (FAB)
257	Me	2-NHOH	—	H	H	M ⁺ +H: 343 (FAB)
258	Me	2-NHCOMe	—	H	H	M ⁺ +H: 369 (FAB)
259	Me	2-NHCOPh	—	H	H	M ⁺ +H: 431 (FAB)
260	Me	2-2-NHSO ₂ Me	—	H	H	M ⁺ +H: 405 (FAB)
261	Me	2-NHSO ₂ Ph	—	H	H	M ⁺ +H: 467 (FAB)
262	Me	2-CO ₂ Me	—	H	H	M ⁺ +H: 370 (FAB)
263	Me ₂ CH-	2-CO ₂ Me	—	H	H	M ⁺ +H: 398 (FAB)
264		2-Br	—	H	H	M ⁺ +H: 463 (FAB)
265		2-Br	—	H	H	M ⁺ +H: 475 (FAB)
266	Me	2-CN	—	H	H	M ⁺ +H: 337 (FAB)


Ex.	Ra	Rb	(Rc)p	Rd'	Re'	DATA: MS m/z
267	Et	2-CN	—	H	H	M ⁺ +H: 351 (FAB)
268	Me ₂ N-	2-CN	—	H	H	M ⁺ +H: 366 (FAB)
269		2-CN	—	H	H	M ⁺ +H: 410 (FAB)
270	Et	3-CN	—	H	H	M ⁺ +H: 351 (FAB)
271	Et	3-NHCOMe	2-Me	H	H	M ⁺ +H: 397 (FAB)
272	Et	3-COOMe	2-Me	H	H	M ⁺ +H: 398 (FAB)
273	Et	3-CONH ₂	2-Me	H	H	M ⁺ +H: 383 (FAB)
274	Et	3-CH ₂ -OH	2-Me	H	H	M ⁺ +H: 370 (FAB)
275	Et	3-CH ₂ OMe	2-Me	H	H	M ⁺ +H: 384 (FAB)
276	Et	3-CH ₂ NMe ₂	2-Me	H	H	M ⁺ +H: 397 (FAB)
277	Et	3-CH ₂ -CN	2-Me	H	H	M ⁺ +H: 379 (FAB)
278	Et	3-CONH ₂	2-Cl	H	H	M ⁺ +H: 403 (FAB)
279	Et	2-(3-Py-O-)	—	H	H	M ⁺ +H: 419 (FAB)
280	Et	2-(2-Py-O-)	—	H	H	M ⁺ +H: 419 (FAB)
281	Et-	2-F	—	2-OMe	H	M ⁺ +H: 374 (FAB)
282	Et-	2-F	—	2-OH	H	M ⁺ +H: 360 (FAB)
283	Et-	2-F	—	3-OMe	H	M ⁺ +H: 374 (FAB)
284	Et-	2-F	—	3-OH	H	M ⁺ +H: 360 (FAB)
285	CF ₃ -	2-F	—	H	H	M ⁺ +H: 384 (FAB)
286	CF ₃ -	2-F	—	2-OMe	H	M ⁺ +H: 414 (FAB)
287	CF ₃ -	2-F	—	3-Me	H	M ⁺ +H: 398 (FAB)
288	CF ₃ CH ₂ -	2-F	—	H	H	M ⁺ +H: 398 (FAB)

Industrial Applicability

[0142] The pharmaceutical drug of the invention has an action to inhibit the activity of glycine transporter and an activity to activate the function of the NMDA receptor. Thus, the pharmaceutical drug of the invention is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.

Claims

1. A pharmaceutical composition for glycine transporter inhibitor which comprises a triazole derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof as the effective ingredient:



(in the formula, the symbols represent the following meanings; Ring A:

- (1) an aromatic carbon ring which may be substituted,

- (2) an aliphatic carbon ring which may be substituted and may be condensed with benzene ring or hetero ring,
 (3) a 5-membered hetero ring which may be substituted and contain one or two nitrogen atoms as the hetero atoms composing the ring and may contain one oxygen atom or sulfur atom as a hetero atom other than the nitrogen atoms and may be condensed with benzene ring or
 (4) a 6-membered hetero ring which may be substituted and contain one nitrogen atom as a ring atom and may contain one oxygen atom or sulfur atom as a hetero atom other than the nitrogen atom and may be condensed with benzene ring;

Ring B or D may be the same or different and each represents aromatic carbon ring which may be substituted, an aliphatic carbon atom which may be substituted, or a hetero ring which may be substituted.

R: H, halogeno-loweralkyl, aryl which may be substituted, hetero ring which may be substituted, cycloalkyl which may be substituted, or $-\text{[Alk1]}_m\text{-X-[Alk2]}_n\text{-Y-R}^1$

wherein R^1 : H, OH, cyano, aryl which may be substituted, hetero ring which may be substituted, cycloalkyl which may be substituted, or lower alkoxy;

X: bond, oxygen atom, S(O)_q , or $-\text{N(R}^2\text{)}_-$;

Y: bond, $-\text{C(O)}_-$, $-\text{C(O)-N(R}^3\text{)}_-$, $-\text{Z}_1\text{-Alk3-}$, or $-\text{N(R}^3\text{)-Alk3-C(O)-}$, with the proviso that R^1 represent other than OH and lower alkoxy, when Y is bond;

Alk1 or Alk2 may be the same or different and each represents lower alkylene, lower alkenylene or lower alkynylene; and m or n may be the same or different and each represents 0 or 1 or $m + n = 1$, provided that X represents bond;


Z_1 : S(O)_q , $-\text{N(R}^3\text{)}_-$, $-\text{C(O)}_-$ or $-\text{C(O)-N(R}^3\text{)}_-$;

Alk3: lower alkylene;

R^2 or R^3 : the same or different from each other and each represents H or lower alkyl;


q: 0, 1 or 2 may be)

2. A pharmaceutical composition for ameliorating learning disability according to claim 1.
 3. A triazole derivative represented by the following general formula (Ia) or a salt thereof:



(in the formula, the symbols represent the following meanings; Ring A' :

- (1) the group represented by the formula:



- (2) naphthalene which may be substituted with one or two substituents selected from the group represented by Rf,
 (3) an aliphatic carbon ring which may be substituted with one or two substituents selected from the group represented by Rf and which may be condensed with benzene ring or hetero ring,
 (4) a 5-membered hetero ring which may be substituted with one or two substituents selected from the group represented by Rf and contain one or two nitrogen atoms as the hetero atoms composing the ring and may contain one oxygen atom or sulfur atom as a hetero atom other than the nitrogen atoms and may be condensed with benzene ring; or
 (5) a 6-membered hetero ring which may be substituted with one or two substituents selected from the group

represented by Rf and which contain one nitrogen atom as the ring atom and may contain one oxygen atom or sulfur atom as a hetero atom other than the nitrogen atom and may be condensed with benzene ring; Ring B': benzene or nitrogen-containing monocyclic hetero ring; or

Ring D': benzene or hetero ring, provided that ring A', B' and D' never simultaneously represents benzene ring;

Ra : a halogeno-lower alkyl, a hetero ring which may be substituted, cycloalkyl which may be substituted, or -[Alk1]m-X-[Alk2]n-Y-R¹

wherein

R¹ : H, OH, cyano, aryl which may be substituted, hetero ring which may be substituted, cycloalkyl which may be substituted, or lower alkoxy;

X: bond, oxygen atom, S(O)q, or -N(R²)-;

Y: bond, -C(O)-, -C(O)-N(R³)-, -Z₁-Alk3-, or -N(R³)-Alk3-C(O)-, with the proviso that R¹ represent other than OH and lower alkoxy, when Y is bond;

Alk1 or Alk2 may be the same or different and each represents lower alkylene, lower alkenylene, or lower alkynylene;

m or n may be the same or different and each represents 0 or 1 or m + n = 1, provided that X represents bond;

Z₁ : S(O)q, -N(R³)-, -C(O)- or -C(O)-N(R³)-;

Alk3: lower alkynylene;

R² or R³: the same or different from each other and each represents H, or lower alkyl;

Rb: halogen atom, lower alkyl which may be substituted with the following substituents, lower alkynyl, halogeno-lower alkyl, hetero ring, hetero ring-O-, cyano, nitro, halogeno-lower alkyl-O-, lower alkoxy, -O-lower alkylene-N(R³)-lower alkylene-C(O)O-R⁶, Z₂-R⁶, or Z₃-R⁷, the substituents of the lower alkyl: OH, cyano, lower alkoxy, amino which may be substituted with lower alkyl;

Z₂: S(O)q, -N(R³)-, -C(O)-, -C(O)-N(R³)-, -N(R³)-C(O)-,

-C(O)-S(O)q-, -N(R³)-S(O)q-, or -C(O)O-;

Z₃: -N(R³)-, or -N(R³)-C(O)-;

R⁶: H, lower alkyl or aryl;

R⁷: OH, or lower alkoxy;

p: 0 or 1;

q: 0, 1 or 2;


Rc: lower alkyl, or halogen atom;

Rd or Re: the same or different from each other and each represents H, halogen atom, lower alkyl, lower alkoxy, OH, lower alkyl, halogeno-lower alkyl, phenyl, halogeno-lower alkyl-O-, amino which may be substituted with lower alkyl or -NR⁸C(O)-R⁹;

R⁸ or R⁹: the same or different from each other and each represents H, or lower alkyl;

Rf: a group represented by Rb, oxo group, or aryl, with the proviso that Rd represents other than H, when the ring A' represents benzene substituted with lower alkoxy and the ring B' represents benzene.

4. A triazole derivative represented by the following general formula (Ib) or a salt thereof:



(in the formula, the symbols represent the following meanings:

Ra, Rc or p: the same group as formula (Ia) described in the claim 3;

Rb': halogen atom, lower alkyl which may be substituted with the following substituents, halogeno-lower alkyl, hetero ring, hetero ring-O-, cyano, nitro, halogeno-lower alkyl-O-, lower alkoxy, -O-lower alkylene-N(R³)-lower alkylene-C(O)O-R⁶, -N(R³)-R⁷, Z₂-R⁶, or Z₃-R⁷;

the substituents of the lower alkyl: OH, cyano, lower alkoxy, amino which may be substituted with lower alkyl;

Z_2' : S(O)q, -C(O)-, -C(O)-N(R³)-, -N(R³)-C(O)-, -C(O)-S(O)q-, -N(R³)-S(O)q-, -C(O)O;

R³, Z₃, R⁸, R⁷ or q: the same group as formula (Ia) described in the claim 3;

Rd': H, lower alkoxyl, OH or lower alkyl;

Re': H, halogen atom, lower alkoxyl, halogeno-lower alkyl, halogeno-lower alkyl-O-, or NR⁸C(O)-R⁹;

R⁸ or R⁹: the same group as formula (Ia) described in the claim 3;

with the proviso that,

(1). at least one of Rd' or Re' represents a group other than H, when Ra is lower alkyl, p = 0:

Rb' represents lower alkyl, lower alkoxyl or halogen atom; or Rd' represents a group except for lower alkyl, provided that Re' is H;

(2). Rb' represents a group other than lower alkyl or lower alkoxyl, when Ra represents α -styryland Rd' and Re' represent H and p = 0;

(3). Rb' represents a group other than lower alkyl, when Ra represents 2-furyland Rd' and Re' represent H and p = 0.)

5. A triazole derivative or a salt thereof according to claim 2, wherein in the triazole derivative represented by the general formula (Ia), the ring B' represents nitrogen-containing monocyclic hetero ring; the ring D' is benzene ring; Rf is halogen atom, lower alkyl, lower alkoxyl, aryl, cyano, carbamoyl or oxo group;

6. 5-[4-(2,6-Difluorophenyl)-5-isopropyl-4H-1,2,4-triazol-3-yl]-2-phenylpyridine;
4-[3-isopropyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzooxadiazole;
3-[3-(3-methoxypropyl)-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]-2-methylbenzonitrile;
3-[3-ethyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl] - 2-methylbenzonitrile;
2-[3-[N-(2-methoxyethyl)-N-methylamino]-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl]benzonitrile;
4-(2,1,3-benzooxadiazol-4-yl)-N-(2-methoxyethyl)-N-methyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-3-ylamine
or a salt thereof.

7. A pharmaceutical composition which comprises the triazole derivative of claim 3 or 4 as an active ingredient.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/04128

A. CLASSIFICATION OF SUBJECT MATTER Int.Cl ⁷ C07D249/08, 249/12, 401/04, 413/14, 405/14, 405/12, 405/04, 403/04, 413/04, 409/10, 417/10, 401/10, 401/14, 405/10, 401/16, 401/12, 495/04, A61K31/41, 31/4439, 31/4155, 31/5377, 31/517, 31/427, 31/416, 31/4709, 31/4725, A61P43/00, 25/28, 25/16, 25/18, 25/14, 25/00, 9/10 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁷ C07D249/08, 249/12, 401/04, 413/14, 405/14, 405/12, 405/04, 403/04, 413/04, 409/10, 417/10, 401/10, 401/14, 405/10, 401/16, 401/12, 495/04, A61K31/41, 31/4439, 31/4155, 31/5377, 31/517, 31/427, 31/416, 31/4709, 31/4725 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) REGISTRY (STN), CAS (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP, 2000-63363, A (Yamanouchi Pharmaceutical Co., Ltd.), 29 February, 2000 (29.02.00), (Family: none)	3-4, 7
A	EP, 608858, A (Dr. Kahl Thomae GmbH), 26 January, 1994 (26.01.94), & DE, 4302051, A & JP, 7-2851, A	1-2, 5-6 1-7
A	EP, 335144, A (Boehringer Ingelheim KG), 09 March, 1989 (09.03.89), & DE, 3808283, A & JP, 1-275571, A	1-7
A	WO, 97/32873, A (Pfizer Research and Development Company, N.V./S.A.), 12 September, 1997 (12.09.97), & BP, 885212, A & JP, 11-506123, A	1-7
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 29 June, 2001 (29.06.01)		Date of mailing of the international search report 10 July, 2001 (10.07.01)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)